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Foreword 
Treatment systems in Europe are increasingly confronted with cocaine use-related problems. After 
opioids and cannabis, cocaine has become the third most commonly reported reason for entering 
drug treatment and accounted for about 8 % of all treatment demands across the EU in 2004. This 
overall figure reflects a wide variation between countries; however, the proportion of new clients 
demanding treatment for cocaine use is estimated to have grown from 10 % to 20 % during the period 
1999–2004 (EMCDDA, 2006). Cocaine use has also become more common among drug users in 
contact with outreach workers or low-threshold agencies, and new findings with respect to treatment 
need to be evaluated in order to adapt addiction services to the new demands.  
The aim of this report is to provide an up-to-date summary of research regarding treatment 
approaches to cocaine dependency, and their effectiveness1. 
New treatment concepts need to be evidence based, calling for a research perspective in the 
evaluation of treatments for cocaine dependence. Nonetheless, innovations in treatment also result 
from individual experiments by clinicians, so that a clinical perspective needs to be added in order to 
obtain a complete overview of developments in the treatment of cocaine dependence. 
In this direction, conferences were organized across Europe to gather further knowledge on cocaine 
treatment by bringing together European researchers and clinicians. For example, a conference on 
clinical research on cocaine took place in April 2006 in Paris organised by the Mission 
Interministérielle de Lutte contre la Drogue et la Toxicomanie. In June 2006, the Federazione Italiana 
Comunità Terapeutiche (FICT) organised in Rome the Congress ‘Cocaina: la FICT tra prassi e 
innovazione: Esperienze a confronto nel contesto italiano’ with the aim of sharing experiences and 
disseminating best practices in relation to cocaine treatment. A similar conference was held in Madrid 
on the 17th of May 2007. 
In conclusion, the present report aims to portray the state-of-the-art in health responses to cocaine 
use, with a special emphasis on mental health problems related to cocaine use. However, there is no 
doubt that current research efforts will in the near future bring about innovations of great importance 
in this field. We hope that this report will support the dynamic research process that is under way and 
at the same time support adjustments in policy regarding addiction services to improve their response 
to cocaine users. 
 
 
 
 
 
 
 
 
 
 
 
                                                     
 
(1) This report reviews the current literature on cocaine treatment, based on a search of the databases Medline, PubMed and 
PsychInfo for the years 2002–07, using the following keywords: cocaine, treatment, dependence. In addition, the reference 
lists of all publications identified through the search were evaluated and reports from European research centres, including 
Trimbos and Cedro in the Netherlands, ISD in Belgium, IFT in Germany and the NTA in the UK, were also considered. Please 
note that the present review does not cover medical complications of cocaine consumption. A review of the literature on this 
topic can be found in the EMCDDA’s Selected Issue 2007 on cocaine. 
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1 History and epidemiological characteristics of cocaine use 
Cocaine is a natural alkaloid isolated from the leaves of the Erythroxylum coca shrub, native to the 
South American mountain chains, which demonstrates marked psychostimulant effects. 
Traditionally, and this is still the case in Latin America, the drug was consumed by chewing coca 
leaves, which, owing to the relatively slow absorption rate, results in low blood concentrations of the 
alkaloid. The experienced acute effects of cocaine are increased euphoria, well-being andself-
confidence, reduced social inhibitions and facilitated interpersonal communication (Hall et al., 1990; 
Gold and Miller, 1997; Marcos et al., 1998). Furthermore, cocaine also reduces fatigue, increases 
vigilance, motor and sexual activity, and facilitates most cognitive functions (Hall et al., 1990; Gold 
and Miller, 1997; Marcos et al., 1998). Its marked gratifying properties significantly contribute to the 
initiation and maintenance of the addictive process (Gardner, 1992; Chen, 1993; Di Chiara, 1995; 
Koob and Le Moal, 1997), and preclinical studies suggest that cocaine has an elevated potential for 
addiction, given that the degree of gratification it provides is significantly greater than that of other 
psychoactive substances (Gold and Miller, 1997).  
It is the pharmacological action of cocaine in blocking catecholamine reuptake in the brain that is 
believed to induce cocaine misuse and even dependence. However, these risks did not become 
known until long after cocaine was chemically isolated and used in the cocaine hydrochloride form. 
Cocaine hydrochloride was first isolated from coca leaves in 1860, and became widely available 
around 1880, even being found as an additive in beverages, creams and toothpaste. Its misuse 
potential led to its use being made illegal in many countries around 1920. 
The illicit use of cocaine continued, but was not as widespread as the use of other illicit substances. 
However, it became a popular drug in the USA in the late 1960s and early 1970s, particularly among 
middle-class or well-to-do users. With the introduction in the early to mid-1980s of the smokeable 
form of cocaine, crack cocaine, cocaine also became popular among the inner-city poor, and 
consumption rates within this demographic segment increased substantially. The availability of this 
South American drug was increased by the geographical proximity to the USA and well-established 
Caribbean and Central American trafficking routes. The spread of cocaine to other industrialised 
nations, mainly in Europe, accelerated when a US crackdown (the Reagan–Bush ‘war on drugs’) 
forced suppliers of cocaine to search for new markets. New trafficking routes to Europe emerged, 
including an air bridge via the Netherlands Antilles to the Netherlands and sea–land routes via West 
Africa and the Iberian peninsula. A subsequent increase in lifetime prevalence of cocaine use in 
Europe was seen during the 1990s, although prevalence rates in Europe did not reach the same 
levels as in the USA.  
In the 2004 United States National Survey on Drug Use and Health, 14.2 % of adults (defined as 12 
years or older) reported lifetime experience with cocaine, and 2.4 % reported recent use; among 
younger adults, the average figure for last year use was 5.1 % (2). In the EU, 3 % of the population 
between 15 and 64 years of age (about 10 million people) have tried cocaine at least once in their 
lives, and 1 in 100 European adults have used cocaine in the last 12 months. Cocaine use is more 
concentrated among younger age groups, and last year experience among 15- to 34-year olds is 
above 2 % in Denmark, Ireland, Italy and the Netherlands and reaches 4% in Spain and the United 
Kingdom (EMCDDA, 2006).  
Among the general population, cocaine use seems to be occasional, occurring mainly at weekends 
and in the recreational settings of bars and discos, where it can reach high levels. Research studies 
conducted among young people in dance and music settings in different countries reveals prevalence 
estimates for cocaine use that are much higher than those found in general populations, with lifetime 
prevalence ranging from 10 % to 75 % (EMCDDA, 2006, selected issues).  
Cocaine can be self-administered through various routes: orally or sublingually via direct application 
to the gums, nasally via snorting, by inhalation in vapour form, by smoking (crack cocaine, coca paste 
or cocarettes) or by injection. From a European perspective, cocaine hydrochloride (powder cocaine) 
                                                     
 
(2) Source: SAMHSA, Office of Applied Studies, 2004 National Survey on Drug Use and Health 
(http://oas.samhsa.gov/nsduh.htm#nsduhinfo). The comparatively higher lifetime figures in the United States may be in part 
related to earlier spread of cocaine use in that country.  
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is the main form of cocaine on the market and is generally either snorted or injected. Coca paste, a 
precursor in the chemical process of producing cocaine hydrochloride, and one of the most widely 
misused substances in South America, is generally not found in Europe. Crack cocaine has emerged 
in several European countries, but for unknown reasons remains confined to specific geographical 
areas, mainly bigger European cities. Crack cocaine is mainly smoked, although injection has also 
been reported where the street market availability of crack cocaine is greater than that of cocaine 
hydrochloride. Freebase cocaine, a smokeable form of cocaine extracted from a mix of an alkaline 
solution of cocaine hydrochloride with a solvent such as ether or acetone, is still used in a few areas 
of Europe, but overall has been replaced by crack cocaine because of the flammability risk of 
smoking freebase, a risk not associated with crack cocaine. Smoking cocarettes (tobacco cigarettes 
to which cocaine hydrochloride is added) seems to be a very rare form of cocaine use and is favoured 
mainly by cocaine users who generally snort cocaine but who have developed nasal complications 
(Haasen et al., 2003a). 
The different routes of administration are associated with differences in bioavailability. The fastest 
onset of action is found with smoked cocaine, followed closely by injected cocaine, whereas snorting 
and oral use have a slower onset of action. The onset of action corresponds to different levels of 
intensity with regard to the effect of cocaine on the brain, which results in differences in the risk of 
dependence. Smoking crack cocaine therefore bears the highest risk of dependence; snorting 
cocaine hydrochloride a lower risk. Cocaine or crack injecting has a high dependence potential and is 
furthermore associated with the risk of transmissible infections such as hepatitis and HIV.  
Patterns of cocaine use also vary between different social groups of users in European cities. A 
multicentre study on patterns of cocaine use in nine European cities found that socially integrated 
cocaine users mainly snorted (95 %) the substance, whereas only a small fraction had smoked or 
injected it, but combined use of cannabis and alcohol was very common (Haasen et al., 2004a). In 
the cities for which data were available, injection was frequent among users in addiction treatment 
settings or in socially marginalised groups. Crack use was usual in Hamburg, London and Paris, and 
to a lesser extent in Barcelona and Dublin. Although crack use among the European general 
population seems to be low, it is an increasing concern among marginalised groups and opioid users 
in some European cities.  
Overall, most cocaine treatment demands in Europe are not related to crack cocaine: around 80 % of 
new outpatient cocaine clients are reported to be using cocaine hydrochloride (cocaine powder) and 
less than 20 % use crack cocaine. However, crack cocaine users may pose particular challenges for 
treatment services as they tend to have a more marginalised social profile than users of cocaine 
powder.  
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2 Current issues in the treatment of problem cocaine use 
To date, little consensus exists on what constitutes effective treatment for cocaine dependence. 
Treatment issues are complicated by the polydrug use of powder cocaine in combination with crack 
cocaine and other substances, especially opiates, which often mask which treatment has been 
beneficial in addressing cocaine use. In addition, the orientation of treatment services around opiate 
dependence problems, alongside the lack of established cocaine treatment programmes, has 
resulted in primary cocaine users being reluctant to present themselves for treatment (Bottomley et 
al., 1997). Some research (e.g. San Molina and Arranz Diez, 2001) suggests that the combination of 
pharmacological and psychotherapeutic interventions is most effective, whereas predominantly 
pharmacological treatment has not been found to be helpful (see section 3). In addition, attrition and 
relapse rates of primary cocaine users are generally high (e.g. Weaver 2007; Higgins et al., 1993). 
More recently, a British Audit Commission report has highlighted the failure of treatment services to 
address adequately the needs of stimulant users, and in particular the treatment needs of women and 
black and ethnic minorities (Audit Commission, 2002)3. The question whether cocaine-targeted or 
non-drug-specific interventions hold the most promise is also not yet answered. 
2.1 Research and evaluation 
Most research concerning treatment for cocaine problems has been carried out in the USA. Because 
of the different history of cocaine and crack use in the USA and the specific sociocultural background 
and treatment context, these findings cannot directly be transferred to the situation in Europe. 
Treatment options for cocaine users in European countries seem to be rather limited and exist in only 
a few countries, and the treatment needs of crack cocaine users are frequently unmet. 
Systematic research or even evaluations of cocaine treatment provision in Europe hardly exist. A 
good overview on the ‘state of the art for evidence based treatments and other interventions’, mainly 
referring to the Netherlands, is given by Rigter et al. (2004). Another study with a focus on Germany 
has been produced by Kraus et al. (2004). Both publications also evaluate the international literature 
on cocaine use and treatment. The effectiveness of the treatment of crack cocaine users was 
reviewed by Thom (2001), but, overall, little research evidence is available assessing the treatment of 
crack cocaine, even in those countries with relatively high local prevalence levels of crack cocaine 
use, such as Germany, Spain, France and the United Kingdom. However, a different approach is 
required to engage crack users in treatment because of the highly erratic patterns of use that are 
associated with the drug. While some new treatment approaches are proving to be promising, 
counselling and psychological therapy remain important where no obvious pharmacological 
replacement therapy is available (Haasen et al. 2003b). 
2.2 Polydrug use and heterogeneity of client profiles 
As multiple substance or polydrug use is the dominant pattern of use among cocaine users, this 
should also be reflected in treatment. Many treatment models in Europe still focus on the heroin user, 
whereas models in the USA target mainly a single substance. Rounsaville et al. (2003) reviewed 
clinical trials on single-drug versus multiple-drug focus in research and concluded by recommending 
that researchers consider moving away from a single-drug focus. 
The increase in treatment demand for cocaine dependence reflects changes in consumption patterns 
and in consumers’ profiles. For example, the recreational or weekend cocaine user is very different 
from a typical heroin addict, for whom most of the treatment models have been developed. 
Consequently, guidances for professionals working with cocaine and crack users have been issued in 
various European countries, such as the one presented by the National Treatment Agency and the 
Royal College of General Practitioners in the United Kingdom (Witton and Ashton, 2002; Ford, 2004). 
This guidance covers a variety of treatment options and their role in cocaine treatment. In Germany, 
practical experiences in the work with crack users were addressed at a conference in 2001 (Dworsky, 
2001), which was followed by the publication of guidance in 2002 (Dworsky, 2002). Specific directions 
                                                     
 
(3) Audit Commission (2002). Changing Habits. The commissioning and management of community drug treatment services for 
adults. London, Audit Commission. 
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for psychiatrists and other medical staff were published in 2004 (Thomasius et al., 2004), which 
presented some general directions regarding standards, work with special subgroups and treatment 
options.  
Data from the United Kingdom suggest that the average time in treatment for cocaine or crack 
dependence is 5–7 years, and that benefits for clients accumulate after a series of treatments (NHS, 
2005). According to a study carried out in the primary care sector, two issues are important to 
optimise treatment outcomes: the adjustment of treatment to individual needs of the user and 
application of the least restrictive and repressive treatment (Ford, 2004).  
A Swedish meta-analysis examined factors that were related to improved treatment outcomes 
(Berglund, 2005). One important beneficial factor appeared to be a strong treatment relationship 
between the recipient and therapist. Another beneficial factor was the additive effect of combining 
different kinds of treatment, although this additive effect was not applicable to all types of treatment. 
Berglund proposed three areas for further research into optimising treatment: the effectiveness of 
short-term treatment compared with long-term treatment; the concurrent use of psychosocial and 
pharmacological treatment; and, finally, interactions between the first and second session of 
intervention. 
The heterogeneity of the cocaine-using population, the considerable variations in patterns of cocaine 
use and the high incidence of concurrent polydrug use create a need for a diverse range of culturally 
appropriate services and treatment responses. For example, recreational cocaine users who are not 
highly involved in a drug culture are unlikely to make demands on service providers (Green et al., 
1994). Conversely, polydrug cocaine users (including methadone-maintained cocaine users) may 
already be in contact with existing opiate-based services but may not report their cocaine use, or their 
cocaine use may not be adequately addressed. Those who use powder cocaine as their main drug 
are more marginal to the established drug culture and are less likely to have knowledge of drug 
services and less willing to identify with the ‘junkie’ lifestyle (Green et al., 1994). In the USA it has 
been suggested that there is a 2- to 4-year time lag between initiation into cocaine use and 
presentation to services depending on the type of user (Kleber, 1988). Consequently, services need 
to be accessible and attractive to the target group in order to ensure early intervention. 
2.3 Treatment entry 
As entry into treatment is a milestone for both the user and the services providing treatment, it merits 
special attention. On entry into treatment a careful assessment should be made to identify needs and, 
in some cases, to create a care plan tailored to the needs of the client (Ford, 2004). 
Cocaine users entering treatment are predominantly introduced by self-referral or family referral. 
Similarly, crack cocaine users entering treatment in Europe tend to be self-referrals or referrals by 
family members or friends (Vanderplasschen et al., 2002; Act-info-FOS, 2004), while in the USA a 
study found that crack cocaine users referred to treatment by the court accounted for almost half of all 
those entering treatment (Siegal et al., 2002). Nonetheless, even in the case of family and friend 
referrals, pressure from the legal system can directly or indirectly contribute to seeking treatment. In 
Ireland for example, users frequently attend services at the request of the courts, or because of 
pending criminal charges (Haasen et al., 2003b). The earlier mentioned US study among crack 
cocaine users found that younger users, users with more severe legal problems and users with prior 
treatment experience were more likely to enter treatment than other users (Siegal et al., 2002). In 
Canada, almost two-thirds of cocaine treatment entrants had legal problems, and half of those were 
introduced to treatment via a court referral (Rush and Wild, 2003). Another study looked at 
differences between cocaine users in Brazil entering treatment for the first time or re-entering 
treatment (Ferri et al., 2002). The results showed that those entering treatment for the first time had a 
tendency towards use of higher dosages, were more likely to be problematic drinkers and had 
increased awareness of their problem. Re-entering users, on the other hand, were more often 
involved in acquisitive crimes, had received social support in entering treatment and suffered from 
more severe dependence. It can therefore be useful to distinguish between first treatment cases and 
clients re-entering treatment when assessing treatment options.  
2.4 Quality assurance 
In Europe, the definition of standards for treatment provision and the implementation of quality 
assurance mechanisms with regard to training of staff, as well as monitoring and evaluation, are 
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increasingly recognised as key to better treatment outcomes (Solberg, 2003). Several European 
countries have focused their attention on the quality aspects of treatment.  
The NTA and Healthcare Commission in the United Kingdom have developed a system to measure 
the quality of treatment and to facilitate improvements based on the results of the assessment. ‘Drug 
treatment should encourage improvement in substance misuse, health and social functioning, and 
reductions in crime and public health risks‘ and evaluation should be based on measured 
performance, e.g. retention rates (NHS, 2005). They also emphasise the importance of focusing on 
local needs and partnerships to establish high-quality treatment and to define quality requirements for 
drug treatment. Wanigaratne et al. (2005) listed speed of treatment entry and treatment duration as 
further factors that can contribute to a higher effectiveness of treatment. Clients with complex needs 
benefited more if the available spectrum of treatment responses was broader. Treatment quality was 
also determined by factors associated with the therapist, such as empathy, collaborative relationship, 
motivational dialogue and willingness to be supervised. 
In a Dutch concept-mapping exercise, involving 90 representatives of three groups of stakeholders, 
the quality framework for addiction treatment was examined (Nabitz et al., 2005). ‘Best practice’ and 
‘performance’ emerged as the main dimensions along with three main conceptual clusters: client 
orientation, treatment practice and attitude of staff. The quality factors that best stood up to scrutiny 
included the evidence base of the treatment approach, respectful interaction with the patient and the 
immediacy of access to treatment. Furthermore, a Belgian study evaluated coordination and 
continuity of care and identified the need for improvements in this field: there was a lack of 
communication between services; client registration was not harmonised; and a care plan existed 
only for 10 % of clients (Vanderplasschen et al., 2002). Finally, in a review of ethical aspects in the 
treatment and care of addicts by Guggenbühl et al. (2000), the authors concluded that a commitment 
to continuity of support is crucial, regardless of the treatment type offered. 
Adequate staff training is (or should be) an integral part of good-quality treatment and may need to be 
adjusted to new circumstances or events. Owing to the increase in crack cocaine use in Germany 
and a parallel increase in the incidence of aggression and violence towards staff at drug help facilities 
(Klee, 2001), experts predict an increasing demand for continuous staff education. In Frankfurt, for 
example, many collaborators in low-threshold services have already been sent to anti-violence and 
de-escalation trainings (Stöver, 2001). In addition, staff may need special training not only in the 
pharmacology of cocaine, but also to further develop skills in, for example, relapse management and 
dealing with psychiatric comorbidity (Wallace, 1992), working with family members (Higgins et al., 
1994) and social networks (McAuliffe et al., 1991). Another important issue for staff is the need to 
provide informality and confidentiality wherever possible (NTA, 2002a).  
The effectiveness of treatment also increases when treatment is able to perform well against quality 
indicators. With regard to the client–therapist relationship, it is important to establish a good 
relationship from the beginning and to show empathy – this is thought to increase the number of 
clients who stay longer in treatment and demonstrate better outcomes (NTA, 2002b). A study on the 
use of the community reinforcement approach among female cocaine users found higher abstinence 
rates, longer abstinence and greater retention among those patients whose therapist’s empathy was 
rated higher (Pantalon et al., 2004). These findings stress the importance of monitoring both 
mechanistic (big picture goals, functional analyses of behaviour, non-drug-related activities, skills 
training and homework) and interpersonal (empathy, response to resistance, and therapeutic alliance) 
processes during treatment.  
Furthermore, treatment quality, as well as the closely connected factor of effectiveness of treatment, 
also needs to be examined. The NTA identified two main success factors associated with more 
effective treatment:  
• improving the clients’ journey through treatment; 
• improving local drug treatment systems.  
Success in these areas implies focusing on the user’s needs – not only drug needs but wider needs 
such as housing, education and employment – and can be improved by short waiting times for 
treatment and good care planning (NHS, 2005).  
One way of measuring the effectiveness of treatment is via long-term follow-up. Thus, several 
longitudinal studies showed the positive effects of treatment on long-term abstinence, with different 
observed outcomes depending on treatment conditions and methodological conditions of the studies. 
For example, 95 % of 131 crack cocaine users who attended a treatment unit in Sao Paulo, Brazil, 
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were followed up after 2 and 5 years (Ribeiro et al., 2007). A notable finding was the very high 
mortality rate of 17.6 % at 5 years, with most deaths attributable to homicide or AIDS. Among the 
remainder, there was a progressive trend towards abstinence over the follow-up period, and there 
was evidence that once abstinence had been achieved it was maintained.  
An evaluation of community treatment outcomes in 708 cocaine-dependent users in the USA 
obtained largely positive results: large decreases in cocaine use were sustained over a 5-year period 
(Simpson et al., 2002). The findings also showed that the severity of drug and psychosocial problems 
at admission was predictive of long-term outcomes, while outcomes improved in direct relation to 
level of treatment exposure. Prospective studies of cocaine treatment outcome have also been 
conducted in the United Kingdom. Thus, the NTORS (Gossop et al., 2002) investigated outcomes 
among stimulant users over a 5-year period and found significant reductions in crack use by those 
using at intake, although over 20 % of patients not using at intake had started using crack cocaine at 
follow-up (Gossop et al., 2002). 
Similarly, a British national postal survey of treatment services reported that cessation of opiate use 
may be associated with an increased likelihood of initiating crack cocaine use (Seivewright et al., 
2000). However, the same survey also reported important improvements among a smaller follow-up 
sample of cocaine misusers, providing further evidence that ‘treatment works’. 
Interesting results were also found in a 1-year follow-up study on the role of social support following 
short-term inpatient treatment (Broome et al., 2002). The results showed that social support networks 
following treatment were more important than variables investigated before or during treatment in 
predicting treatment outcome. This indicates that drug use is not only influenced by the 
pharmacological properties of the substance but is at least as much affected by the social context of 
the user. Thus, higher rates of relapse were observed among those with no positive support for 
abstinence at home and/or those who were living with a drug or alcohol user. In summary, support 
from family and peers appears to play a substantial role in lowering the risk of cocaine relapse, even 
after short-term treatments. 
 
EMCDDA literature reviews — Treatment of problem cocaine use 
 
 
 
13
3 Pharmacological treatment  
Distinct pharmacological therapies have been developed mainly on the basis of the modification of 
cerebral dopaminergic transmission (see section 3.1). In general, pharmacotherapies follow two 
principal strategies. The administration of dopamine receptor antagonists aims to counteract 
cocaine’s gratifying effects, while the opposite effect is sought with agents that facilitate dopaminergic 
transmission. These facilitatory agents are generally used to prevent dopaminergic depletion 
observed during cocaine withdrawal or to reduce cravings during abstinence (see reviews by 
Gorelick, 1995; McCance, 1997; Gorelick et al., 2004). Other pharmacological agents, acting on 
serotonergic or noradrenergic transmission, have also been tested for their potential therapeutic 
benefits regarding cocaine dependence. To date, however, the most innovative treatment being 
tested is the cocaine vaccine, the aim of which is to block the desired effects of cocaine, and thus 
reduce its abuse potential, by producing cocaine antibodies (see also section 3.3). Finally, a special 
case in the treatment of cocaine dependence arises in patients who are also dependent on opioids. 
Opioid maintenance treatment is the most commonly used pharmacological treatment for opioid 
dependence, which in the case of additional cocaine use must be optimised (see also section 3.4).  
Different stages in the addiction process have been identified and are commonly labelled initiation, 
continuation, withdrawal and relapse. These stages are characterised by the actions of specific 
neurotransmitters on different brain structures and neural circuits. In the first stage (initiation of use), 
dopamine (DA) is thought to play an important role in the acute reinforcing effects of the drug, with 
the ventral tegmental area (VTA) and the nucleus accumbens (NcA) as the primary areas of interest. 
In the second stage (continued drug use), several neurotransmitters are involved, including DA in the 
NcA, corticotrophin-releasing hormone (CRH) in the amygdala and glutamate in the frontal–cingulate 
circuit. In the third stage (withdrawal), glutamate and noradrenaline in the locus coeruleus seem to be 
crucial. Finally, in the fourth stage (relapse after sustained abstinence), the orbitofrontal cortex, the 
anterior cingulate gyrus and the amygdala are important brain regions in the addictive process, with 
noradrenaline and CRH involved in the brain stress system (stress-induced relapse) and gamma-
aminobutyric acid (GABA) and glutamate involved in the compulsive and habit system (cue-induced 
relapse). This short description of the neurobiology of addiction clearly reveals that there are many 
different ways to intervene in the addictive process of cocaine self-administration. For example, the 
rewarding process can be blocked, illicit drugs can be replaced by other less harmful or less addictive 
compounds, hyperactivity in the stress axis can be prevented and the balance between the different 
neural systems can be restored. In the following review of currently available pharmacological 
treatments for cocaine dependence, many of these neurotransmitter systems and neural circuits are 
targeted to either reduce cocaine use or prevent relapse during sustained abstinence. 
3.1 Substances for relapse prevention 
The pharmacological treatment approaches reported below all aim at relapse prevention. Unlike 
opiate withdrawal, acute cocaine withdrawal is less dramatic and usually does not necessitate 
medication. In the last two decades, a great number of compounds belonging to different 
pharmacological classes have been tested for their effectiveness in the prevention of relapse and the 
promotion of stable abstinence in cocaine addicts. These drug classes include (see also the following 
reviews on pharmacological approaches to cocaine dependence: van den Brink and van Ree, 2003; 
Sofuoglu and Kosten, 2005; Wiesbeck and Dursteler-Macfarland, 2006): 
• dopamine receptor agonists (e.g. bromocriptine, pergolide, DAS431, d-amphetamine); 
• dopamine partial receptor agonists (e.g. terguride, BP897); 
• dopamine reuptake inhibitors (e.g. amantadine, mazindol, methylphenidate, GBR12909 
(vanoxerine), various tricyclic antidepressants and SSRIs); 
• dopamine metabolism inhibitors (e.g. selegiline, disulfiram); 
• dopamine antagonists (e.g. haloperidol, flufenazine, flupenthixol, ritanserine, risperidone, 
ecopipam); 
• GABAergic compounds (e.g. baclofen, gabapentin, tiagabine, lamotrigine, valproate, 
carbamazepine, topiramate); 
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• β-adrenergic antagonists (e.g. propanolol, labetalol); 
• opioids (e.g. naltrexone, buprenorphine, cyclazone); 
• cortisol synthesis inhibitors and glucocorticoid receptor antagonists (e.g. ketoconazole, 
metyrapone, dexamethasone); 
• calcium channel blockers (e.g. nimodipine, isradipine); 
• various antidepressants (e.g. desipramine, imipramine, fluoxetine, venlavaxine, bupropion, 
gepirone, selegiline). 
In a systematic review on medications used in the prevention of cocaine relapse, Silva de Lima et al. 
(2001) were able to detect more than 1 000 citations (1966–2000), from which they identified 49 
different efficacy studies of acceptable methodological quality: 20 on antidepressants (14 on 
desipramine), five on carbamazepine, 13 on dopamine agonists and 11 on miscellaneous 
interventions (e.g. phenytoin, nimodipine, lithium carbonate, naltrexone). Dropout rates ranged from 
0 % to 84 %, but in general the proportion of patients remaining in treatment was similar between 
those taking active medication or placebo. The same was true for cocaine-positive urine samples: 
again no significant differences were found in a statistical meta-analysis regardless of the type of 
medication or dosage. Furthermore, no significant differences between medications and placebo 
were generally observed in terms of specific side-effects. More recent reviews have revealed that 
disulfiram appears to have the most consistent effect in preventing relapse, whereas most other 
medications show very inconsistent results or still need further evaluation in larger controlled trials 
(Vocci and Elkashef, 2005; Vocci and Ling, 2005; Sofuoglu and Kosten, 2006). Nonetheless, a 
detailed description of each drug class is necessary in order to understand its mechanisms and its 
potential therapeutic benefits.  
 
3.1.1 Dopamine receptor antagonists 
To date, no conclusive findings on the efficacy of dopaminergic receptor antagonists in the treatment 
of cocaine dependency have been reported. However, some clinical studies have indicated that 
dopaminergic receptor antagonists, primarily acting on D2 dopamine receptors, such as classical 
neuroleptics, can partially block the subjective effects of cocaine in humans and thereby potentially 
reduce its consumption (Berger et al., 1989; Sherer et al., 1989; Khalsa et al., 1994). Nevertheless, 
this therapeutic approach suffers from two main problems. Firstly, chronic administration of such 
agents induces anhedonia and undesirable extrapyramidal motor effects, resulting in elevated 
treatment dropout rates (Kosten and Kleber, 1988; Decker and Ries, 1993). Secondly, repeated 
treatment with DA antagonists can lead to an increase in dopaminergic postsynaptic receptor 
sensitivity, which, indirectly, can increase the subjective effects of cocaine and thereby its abuse 
liability (Goldfrank and Hoffman, 1991; Kosten and McCance, 1997). 
Regarding specific typical antipsychotic drugs, clinical trials have been conducted mainly on dually 
diagnosed (substance use disorder and psychotic disorder) patients, with only a few substances 
showing an effect on cocaine-dependent subjects without a second diagnosis. For example, 
flupenthixol treatment resulted in a reduction in cocaine use, especially in cocaine users with 
additional alcohol abuse (Soyka and De-Vry, 2000). In contrast to classical neuroleptics, new atypical 
antipsychotics used in the pharmacotherapy of cocaine dependence have the advantage of 
presenting a low profile of undesirable effects. However, results from studies employing atypical 
antipsychotic drugs in cocaine-dependent patients have not yet shown conclusive results (Meil and 
Schechter, 1997; Farren et al., 2000; Grabowski et al., 2000). Nonetheless, the atypical antipsychotic 
drug with the most reported benefit for cocaine dependence was found to be quetiapine, which 
appeared to have a particularly positive effect on substance-induced anxiety disorder (Sattar et al., 
2004). Another atypical antipsychotic drug, risperidone, was tested under the hypothesis that it could 
reduce cue-elicited cocaine craving among cocaine-dependent individuals. However, the results did 
not support this hypothesis and, although a reduction in craving over time was observed, there were 
no significant differences among users treated with risperidone compared with those taking a placebo 
(Smelson et al., 2004).  
Newer atypical antipsychotic substances such as ziprasidone and ondansetron are only at a 
preclinical experimentation stage but appear to be promising pharmacological agents in treating 
cocaine dependence (Davidson et al., 2004; Cleveland et al., 2005). For example, ondansetron 
(0.2 mg/kg) injected 3.5 h after cocaine self-administration in rats reduced cocaine intake the 
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following day while having no effect on water intake (Davidson et al., 2004). Promising therapeutic 
potential is also attributed to the D1 antagonist adrogolide. Preclinical trials revealed that adrogolide 
attenuated the ability of cocaine to induce cocaine-seeking behaviour and did not itself induce 
cocaine-seeking behaviour in a rodent model of cocaine craving and relapse. Furthermore, clinical 
trials have shown that intravenous injections of adrogolide in cocaine-dependent users reduced 
cocaine craving and other cocaine-induced subjective effects (Giardina and Williams, 2001). Finally, 
preclinical trials with a selective D3 antagonist revealed an inhibition of cocaine-seeking and cocaine-
enhanced brain reward in rats (Vorel et al., 2002). In another study, however, the D3 antagonist 
nafadotride appeared to increase cocaine self-administration in rats (Caine et al., 1997). The unclear 
role of D3 dopamine receptors is potentiated by the finding that D3 agonists have been shown to 
reduce cocaine self-administration in rats (Caine et al., 1997; Le Foll et al., 2000). Future research is 
required to elucidate the role of D3 in drug abuse to clearly determine the therapeutic potential of D3 
blockading agents in cocaine dependence. 
 
3.1.2 Dopamine agonists 
Cocaine acutely enhances dopamine transmission and chronically decreases dopamine 
concentrations in the brain. Therefore, during the initial period of abstinence after cocaine use, 
subjects may experience symptoms such as depression, fatigue, irritability, anorexia and sleep 
disturbances. One treatment strategy to counteract these effects has been to administer dopamine 
agonists, such as amantadine, bromocriptine and pergolide. In a randomised placebo-controlled trial, 
subjects receiving amantadine used significantly less cocaine during the trial than those taking a 
placebo (Kampman et al., 2000). In a screening trial, amantadine-treated cocaine-dependent patients 
were retained significantly longer than placebo and were more likely to be cocaine abstinent 
(Shoptaw et al., 2002). However, a large number of studies have reported negative results. Thus, in a 
pilot trial with cocaine-dependent subjects, amantadine did not modify the choice to self-administer 
cocaine (Collins et al., 2003), while a clinical trial testing methadone tapering plus amantadine to 
detoxify heroin-dependent cocaine users showed no efficacy with respect to retention in treatment or 
reduction in use or cocaine craving (Perez de los Cobos et al., 2001). Furthermore, mazindol, a 
dopamine and noradrenaline reuptake inhibitor used for the treatment of obesity, was also tested in 
cocaine-dependent subjects. The results showed either no difference compared with placebo (Stine 
et al., 1995) or a statistically non-significant treatment effect (Margolin et al., 1995). The efficacy of 
bromocriptine in the treatment of cocaine dependence was tested in an open-label study (Montoya et 
al., 2002) and in a double-blind placebo-controlled study (Handelsman et al., 1997). These and 
previous studies did not find any evidence to support the clinical use of bromocriptine in the treatment 
of cocaine dependence. The dopamine agonist pergolide was studied in a preliminary placebo-
controlled trial, but was not associated with any significant reduction in cocaine use compared with 
placebo (Levin et al., 1999). In a double-blind, multiple-dose comparison, pergolide also did not show 
any positive effect in the treatment of cocaine dependence (Malcolm et al., 2001). In another placebo-
controlled study, pergolide was ineffective in reducing craving or cocaine use (Focchi et al., 2005). 
Finally, a Cochrane review analysed 17 studies on the use of dopamine agonists, including a total of 
1 224 patients, and came to the conclusion that current evidence does not support the clinical use of 
dopamine agonists in the treatment of cocaine dependence (Soares et al., 2003). 
 
3.1.3 MAO inhibitors 
Therapeutic approaches that involve dopaminergic transmission-facilitating agents for the treatment 
of cocaine dependence include a great variety of drugs with distinct molecular mechanisms, such as 
DA precursors and releasers or monoamine oxidase (MAO) inhibitors, and selective serotonin 
reuptake inhibitors (SSRIs). The results of a variety of clinical investigations show that these agents 
are mildly effective in reducing craving and, to some extent, in reducing the signs and symptoms of 
cocaine dependence (for a review see Crosby et al., 1991; Gorelick, 1995; McCance, 1997; Bartzokis 
et al., 1999; Kampman et al., 2000). For example, the MAO-B inhibitor selegiline was tested as a 
transdermal patch in cocaine-dependent subjects and it was found that selegiline reduces the 
physiological and subjective effects of cocaine (Houtsmuller et al., 2004). However, in preclinical 
trials, MAO-A inhibitors did not reduce cocaine self-administration in rats (e.g. Pepper et al., 2001). 
 
3.1.4 Antidepressants 
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Various antidepressants have also been tested with respect to their effect on cocaine use in cocaine-
dependent subjects. Since the 1980s, desipramine has been investigated for its effects on the 
noradrenergic system, initially with promising results (Gawin et al., 1989), which have not been 
corroborated in subsequent clinical trials (Arndt et al., 1992; Kosten et al., 1992). Nonetheless, some 
more recent studies have indicated a possible therapeutic role of desipramine in cocaine 
dependence. Thus, a double-blind, placebo-controlled study showed that desipramine-treated 
subjects were retained in treatment significantly longer than those receiving placebo (Campbell et al., 
2003), while another placebo-controlled double-blind study showed desipramine and contingency 
management (CM) to have independent and additive effects in reducing cocaine use in 
buprenorphine-maintained patients (Kosten et al., 2003). SSRIs have also been tried in cocaine-
dependent users, but without conclusive results (Covi et al., 1995; Petrakis et al., 1998). A Cochrane 
review on the efficacy of antidepressants for cocaine dependence concluded that there was no 
current evidence supporting the clinical use of antidepressants in the treatment of cocaine 
dependence (Lima et al., 2003). Thus, of the 18 studies included, desipramine performed better than 
placebo, but results reached only non-significant trends. Imipramine performed better than placebo in 
only one single trial, while only one single trial showed that fluoxetine patients were less likely to drop 
out. A more recent review also found no evidence to justify the use of antidepressants in patients with 
substance use disorders without comorbid depression (Torrens et al., 2005). Recent trials with 
modern antidepressants have also shown that paroxetine, pentoxifylline, riluzole, pramipexole and 
venlafaxine (Ciraulo et al., 2005a; Streeter et al., 2005), fluoxetine (Harris et al., 2004) and 
nefazodone (Passos et al., 2005) have no effect on cocaine use, while only one trial found that 
venlafaxine resulted in a small but significant reduction in cocaine use (Foltin et al., 2003). The only 
substance which has shown promising results in the reduction of cocaine use is reboxetine (Szerman 
et al., 2005), which, however, requires further corroborative studies. 
 
3.1.5 Stimulants 
With a perspective similar to that of methadone maintenance treatment in the case of opiate 
addiction, diverse psychostimulating substances have been proposed as substitution therapies. The 
use of methylphenidate or phenmetrazine as a substitution agent has, however, led to unsatisfactory 
results. Although both substances, at the outset, appeared to decrease craving, they did not reduce 
cocaine use (Grabowski, 1994), and in the long term they appeared to increase both cocaine 
consumption and craving (Gawin et al., 1985; Tennant et al., 1993). These undesired effects are 
believed to be caused by the marked drug abuse liability of these medications (Litten and Allen, 
1997). However, methylphenidate appears to be effective in decreasing cocaine use amongst 
patients with co-occurring attention deficit disorder (Khantzian et al., 1984; Biederman et al., 1999; 
Castaneda et al., 2000), suggesting a self-medicating use of cocaine. 
Dexamphetamine (dextroamphetamine), a stereoisomer of amphetamine with greater stimulant 
properties than amphetamine, has also been investigated as a potential therapeutic agent in cocaine 
dependence. An initial randomised placebo-controlled study showed dexamphetamine to be effective 
in reducing cocaine use (Grabowski et al., 2001), while a small randomised study comparing 
dexamphetamine with placebo showed equal retention rates in both groups, but better outcome 
(fewer cocaine-positive urine samples) in the group receiving dexamphetamine. However, the group 
differences did not reach statistical significance (Shearer et al., 2003). A descriptive study of the case 
notes of cocaine-dependent patients consulting a psychiatrist found that dexamphetamine treatment 
helped to reduce cocaine use and to retain patients in treatment (Moselhy and El-Sheikh, 2004). 
Reports on the dexamphetamine treatment of cocaine dependence are, however, still inconclusive 
and need to be replicated in larger controlled trials. 
Finally, the use of stimulants with minor addictive potential, such as pemoline and diethylpropion, has 
had relatively little success. Thus, in a clinical trial, diethylpropion treatment was associated with a 
significant number of side-effects, without any obvious therapeutic efficacy, so that it was not 
considered a candidate for future medication development (Alim et al., 1995). An open-label trial with 
pemoline also found no therapeutic benefit in the treatment of cocaine abuse in methadone-
maintained patients (Margolin et al., 1996). 
In summary, clinical trials and therapeutic approaches using only dopaminergic transmission-
facilitating agents for the treatment of cocaine dependence have been demonstrated to be only mildly 
effective in reducing cocaine use and associated symptoms, such as craving (for further information 
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consult reviews by Crosby et al., 1991; Gorelick, 1995; McCance, 1997; Bartzokis et al., 1999; 
Kampman et al., 2000; Grabowski et al., 2004a). 
 
3.1.6 Opiate antagonists 
It is thought that the endogenous opioid system is also involved in the cocaine reinforcement process. 
Furthermore, the administration of naloxone has been found to reduce the reinforcing effects of 
cocaine in self-stimulating behaviour in rats (Bain and Kornetsky, 1987). Naltrexone has also been 
shown to reduce the reinforcing effects of low doses of cocaine (De Vry et al., 1989). However, the 
results are inconclusive, and it is therefore doubtful whether it is useful to pursue this line of research 
(McCance, 1997). Nonetheless, preliminary studies have shown that naltrexone may be effective in 
reducing both cocaine and alcohol use in subjects using both substances (Oslin et al., 1999), while 
another study has shown that naltrexone in combination with coping skills training can reduce cocaine 
use in dependent patients (Schmitz et al., 2001).  
 
3.1.7 GABAergic agonists and glutamatergic antagonists 
It has also been suggested that GABAergic agonists, and especially glutamatergic antagonists, could 
be useful agents in the treatment of cocaine addiction. A recent laboratory study evaluating how 
maintenance on baclofen influenced smoked cocaine’s reinforcing and subjective effects, as well as 
mood and cocaine craving prior to and after the initiation of cocaine use, showed baclofen to 
decrease self-administration of low doses of cocaine in non-opioid-dependent patients seeking 
treatment for cocaine dependence, whereas no effect was observed in opioid-dependent cocaine 
users (Haney et al., 2006). Gabapentin treatment for cocaine dependence has recently been tested in 
a randomised placebo-controlled study in 129 cocaine-dependent individuals (Bisaga et al., 2006). 
The gabapentin group received 3 200 mg per day over 12 weeks and the outcome showed trends 
favouring only the gabapentin group, although on most measures there were no differences between 
the gabapentin-treated and placebo groups. Previously, two pilot studies with a lower dose of 
gabapentin also failed to show an effect that could be clinically useful (Hart et al., 2004; Haney et al., 
2005). Despite the lack of evidence of an effect of gabapentin, the authors concluded that further 
studies were required in order to fully evaluate the potential of gabapentin as a relapse preventative 
agent for cocaine treatment. 
Antiepileptic drugs, such as valproate and carbamazepine, have also failed to deliver promising 
results in the management of cocaine dependence. Small initial studies found that carbamazepine 
had no effect (Cornish et al., 1995; Kranzler et al., 1995; Montoya et al., 1995), while a more recent 
study showed that carbamazepine was effective only in cocaine-using individuals with a comorbid 
affective disorder (Brady et al., 2002). Similarly, a Cochrane review concluded that there was no 
existing evidence supporting the clinical use of carbamazepine in the treatment of cocaine 
dependence, and larger randomised studies, which would be needed, should take into account the 
fact that such time-consuming efforts should be reserved for medications for which more relevant and 
promising evidence is available (Lima et al., 2002). Nonetheless, a more recent study did show that 
depression and irritability were reduced in antidepressant-treated compared with placebo-treated 
crack cocaine-dependent patients, but no group difference in sustained abstinence or negative urine 
samples was observed (Campbell et al., 2003). With respect to valproate, an open pilot project with 
divalproex (a combination of sodium valproate and valproic acid) showed a retention rate of 79 % at 
week 4 and 50 % at week 8 (Myrick et al., 2001), while a recent randomised controlled trial (RCT) 
found no support for the effectiveness of valproate in the treatment of cocaine dependence (Reid et 
al., 2005a). 
Topiramate is another antiepileptic drug being considered for the treatment of cocaine dependence 
(Johnson, 2005; Cubells, 2006). A pilot double-blind placebo-controlled trial found that subjects in the 
topiramate group were more likely to be abstinent from cocaine than those in the placebo group 
(Kampman et al., 2004). 
Other GABAergic agents that have been tested for their effect in reducing cocaine use in cocaine-
dependent subjects are tiagabine and vigabatrin. In a randomised pilot study, tiagabine was found to 
moderately improve cocaine-free urine samples in cocaine-dependent methadone-treated patients 
(Gonzalez et al., 2003). In a comparative study, tiagabine, in contrast to sertraline and donepezil, was 
found to be associated with lower cocaine use in cocaine-dependent subjects (Winhusen et al., 
2005), while an experimental study showed that tiagabine treatment attenuated some of the 
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subjective effects of cocaine (Sofuoglu et al., 2005). Two small preclinical studies have found 
vigabatrin (gamma-vinyl GABA (GVG)) to be a promising substance for the treatment of cocaine 
dependence by inhibiting cocaine-induced increases in dopamine levels (Schiffer et al., 2003).  
Modafinil is also a substance being tested for its effect in reducing cocaine use in cocaine-dependent 
subjects and is involved in the glutamate reward circuit. A wakefulness-promoting drug approved for 
the treatment of narcolepsy, modafinil is a substance that increases brain glutamate, and its 
stimulant-like action is thought to reduce cocaine withdrawal symptoms, such as hypersomnia, 
anergia, depressed mood, hyperphagia, psychomotor retardation and poor concentration (Dackis and 
O’Brien, 2003). In a pilot study, modafinil treatment blunted cocaine euphoria without intensifying 
cocaine craving (Dackis et al., 2003). A recent double-blind, placebo-controlled trial provided 
preliminary evidence that modafinil improves clinical outcome when combined with psychosocial 
treatment (Dackis et al., 2005).  
 
3.1.8 Disulfiram 
Disulfiram, commonly known as Antabuse and used in the treatment of alcoholism, has also been 
tested for an effect in cocaine dependence. Thus, it has been observed that the quantity and 
frequency of cocaine use were reduced in disulfiram-treated subjects to a significantly greater extent 
than in those treated with placebo (George et al., 2000; Petrakis et al., 2000). As disulfiram deters 
concomitant alcohol consumption, it is thought that the drug also affects the desire to use cocaine 
(McCance, 1997; for a review see Rawson et al., 2002). These beneficial effects of disulfiram on 
cocaine and alcohol use have been shown to be sustained during a 12-week follow-up (Petrakis et 
al., 2000). Furthermore, a large randomised, placebo-controlled study confirmed the effectiveness of 
disulfiram treatment in reducing cocaine use, and appeared to exert a direct effect on cocaine use 
rather than through reducing concurrent alcohol use (Carroll et al., 2004). However, men treated with 
disulfiram tended to have better outcomes than men not treated with disulfiram, whereas women had 
an intermediate outcome regardless of whether or not they had received disulfiram (Nich et al., 2004). 
The authors suggested that disulfiram treatment be combined with psychosocial interventions, e.g. 
cognitive–behavioural therapy (CBT), in order to enhance treatment adherence and effectiveness 
(Gossop and Carroll, 2006). 
 
3.1.9 Other pharmacological agents 
A medication screening trial evaluated reserpine, gabapentin and lamotrigine, and found that the best 
results, in terms of reduction in cocaine use, were achieved in the reserpine group, suggesting that 
this drug merits further investigation (Berger et al., 2005). Another antihypertensive medication, the 
calcium channel blocker isradipine, was tested with respect to its treatment potential, but, although 
preclinical studies suggested that isradipine may antagonise the abuse liability of cocaine, the drug 
did not affect cocaine-induced euphoric mood in cocaine-using volunteers (Roache et al., 2005). 
Kappa opioid agonists are still in the phase of being tested in animal studies, but have been shown to 
induce a decrease in cocaine self-administration in rhesus monkeys (Mello and Negus, 2000; Preston 
et al., 2004; Stevenson et al., 2004). However, L-tryptophan, a serotonergic precursor, showed no 
effect on cocaine use in a controlled clinical trial in cocaine-dependent subjects (Jones et al., 2004). 
Another substance being studied for its effect on cocaine use is the steroid hormone progesterone, 
with initial trials showing that acute progesterone treatment may attenuate some of the subjective 
effects of cocaine as well as cocaine-induced diastolic blood pressure increases. These findings 
suggest that progesterone might have potential therapeutic benefits in cocaine dependence (Sofuoglu 
et al., 2002, 2004). 
The list of drugs tested for the treatment of cocaine dependence would be longer if it were to include 
further substances tested without any positive results, such as the non-steroidal anti-inflammatory 
drug (NSAID) celecoxib, which showed no evidence of effectiveness (Reid et al., 2005b). 
 
3.1.10 Clinical practice 
Considering the lack of real substantial efficacy of any of the above-mentioned drugs, prescribing 
practices have developed that are not necessarily evidence based but reflect clinical experience. 
Seivewright et al. (2000) reviewed a substantial range of pharmacological treatments employed by 
treatment services in the United Kingdom. The two most frequently used antidepressants were 
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fluoxetine and desipramine, used by 21 and 10 services respectively, for which there is some 
supporting evidence (Levin and Lehman, 1991; Batki et al., 1993; Covi et al., 1995; Warner et al., 
1997), but also negative reports (e.g. Grabowski et al., 1995). Amitriptyline, a tricyclic antidepressant, 
was prescribed by four services to approximately 21 clients, although a report by Keaney et al. (2002) 
reported complications with the use of tricyclic antidepressants when detoxifying polydrug patients. 
Despite the controversy associated with prescribing benzodiazepines to illicit drug users, many 
services appear to prescribe them for their sedative effects in withdrawal states (Darke et al., 1994), 
while a minority of services prescribe antipsychotics to address cocaine-induced psychosis.  
3.2 Other pharmacological measures 
Cocaine or amphetamine maintenance programmes as prophylaxis of illegal substance consumption 
have been tried in psychostimulant addiction programmes (Bagasra et al., 1992), with the goal of 
reducing withdrawal symptomatology and relapse prevention (Siegel et al., 1986; Llosa, 1991, 1994), 
but with little success (Fleming and Roberts, 1994). In the United Kingdom, cocaine was prescribed 
for cocaine dependence to a limited extent until 1968, with physicians prescribing injectable cocaine 
to approximately 1 000 clients. However, with the introduction of regional drug clinics in 1968, this 
practice was immediately stopped (Strang and Edwards, 1989). A few trials have been carried out 
with cocaine substitution (prescribing cocaine for the dependent subject), but there have been no 
RCTs yet (Haasen, 2003; Stohler, 2004). 
3.3 Immunisation and vaccination 
Immunisation and vaccination are two strategies with a long tradition and very little empirical proof of 
effectiveness (Kantak, 2003). In (passive) immunisation, catalytic antibodies are injected that bind 
cocaine and subsequently hydrolyse cocaine into the inactive products ecognine methyl ester and 
benzoic acid. 
A cocaine vaccine has also been proposed; this would attempt to block the effects of cocaine using 
cocaine antibodies (Bagasra et al., 1992; Garcia Sevilla, 1997; Navarro and Rodriguez De Fonseca, 
2000). This unique approach to the pharmacotherapy of cocaine addiction was initiated by 
immunisation experiments that demonstrated specific cocaine antibody production in animals 
(Carrera et al., 1995, 2000; Fox, Kantak et al., 1996; Fox, 1997). Cocaine-specific antibodies can 
sequester cocaine molecules in the bloodstream, thereby allowing naturally occurring enzymes 
(cholinesterases) to convert cocaine into inactive metabolites, which are then excreted. As the 
antibodies cannot cross the blood–brain barrier, the vaccine is not expected to have any direct 
psychoactive effect. As the antibodies prevent cocaine from having an effect, the reinforcing effect of 
continued cocaine use will be dampened. Furthermore, the vaccine persists for months, so there is no 
need for daily administration of medication. 
A randomised, double-blind, placebo-controlled clinical trial involving 34 former cocaine users was 
carried out to assess the safety and immunogenicity of the therapeutic cocaine vaccine TA-CD 
(Kosten et al., 2002). The results of this trial showed that the vaccine induced cocaine antibodies in a 
time- and dose-dependent manner and that it was well tolerated with no serious adverse events 
during 12 months of follow-up. This trial was then followed up by an open-label, 14-week, dose 
escalation study evaluating the safety, immunogenicity and clinical efficacy of the cocaine vaccine 
(Martell et al., 2005). Ten cocaine-dependent subjects received a total dose of 400 μg of vaccine in 
four injections over the course of 8 weeks and eight cocaine-dependent subjects received a total 
dose of 2 000 μg of vaccine in five injections over the course of 12 weeks. The results showed a high 
completion rate, no serious adverse events, good tolerance and a significantly higher likelihood of 
cocaine-free urine in the high-dose group at 6 months. The results are most encouraging when 
compared with other pharmacological strategies, but will have to be replicated in further studies. 
Despite the promising results, some ethical questions have arisen with respect to the vaccine 
(Ashcroft and Franey, 2004; Katsnelson, 2004): Can an addict truly consent to treatment? Should 
governments compel high-risk individuals to be vaccinated, in order, for example, to reduce 
criminality associated with cocaine dependence? If so, who would decide who is at risk? These 
questions have been discussed in several advisory panels both in the USA as well as in the United 
Kingdom, where the British biotech company Xenova, which holds the licence for the vaccine, is 
located. Furthermore, one of the major drawbacks of the vaccine is that a crucial factor in its 
effectiveness is the subject’s continued motivation to take booster vaccinations (Kantak, 2003), and 
this necessary motivation is by itself one of the most effective elements of any cocaine treatment. 
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Separate from efforts to develop a strategy of treating cocaine dependence by immunisation or 
vaccination, efforts are also being made to develop immunotherapy for cocaine overdose. By using 
protein-based technology, anti-cocaine monoclonal antibodies have been developed that bind 
cocaine in the bloodstream, thereby inactivating its toxic effects (Carrera et al., 2005). The antibody 
GC92H2 has been tested in mice and was found to significantly block cocaine toxicity and therefore 
prevent death even after cocaine injection. Further studies are likely to determine whether this 
treatment will be possible and effective in humans. 
3.4 Optimising opioid treatment in the presence of additional cocaine use 
As many dependent cocaine users are also heroin or other opiates users, they are often receiving 
methadone maintenance treatment (MMT) or some other agonist maintenance treatment for the 
treatment of heroin misuse. In the USA, for example, approximately 50 % of all methadone treatment 
applicants also use cocaine (Katz et al., 2002). In Europe, numbers vary greatly and are generally 
correlated with the overall number of cocaine users in each country. Usually, MMT is accompanied by 
some psychosocial intervention or drug counselling, but this occasionally focuses only on cocaine 
use. As cocaine use is widespread among patients in MMT and often interferes with this therapy, 
many experts and projects in this field have demanded the development of specific strategies to deal 
with cocaine and crack co-abuse. To date, cognitive behavioural based approaches combined with 
contingency management (CM) seem to have the most beneficial results for cocaine-abusing clients 
in MMT (e.g. Silverman et al., 1998; Rowan-Szal et al., 2005), although CM is rarely practised in 
Europe (see also section 4.2). 
Following enactment of a law in California requiring all MMT patients to undergo drug counselling, the 
cocaine-using population within the MMT programme showed significant reductions in cocaine use 
after counselling compared with before the implementation of the new law (Kletter, 2003). The study 
also found similar reductions in heroin use. Crack users receiving MMT who do not reduce their 
cocaine use exhibit poorer compliance and poorer psychological health and increased acquisitive 
crime rates (Mitcheson et al., 2007), and also experience negative sequelae (Bovasso and Cacciola, 
2003). An Australian study also found that the outcome of opioid substitution therapy was poorer if 
cocaine use was continued, but was significantly improved when cocaine use decreased (Williamson 
et al., 2006a). This emphasises the importance of concentrating on cocaine co-use during MMT. 
Agonist maintenance treatment is considered the first-line treatment for opioid dependence (van den 
Brink and van Ree, 2003). If additional cocaine use hampers the outcome of maintenance treatment, 
a first measure would be to optimise this treatment. Thus, an important factor determining treatment 
outcome is the dose of opioid agonist administered. A Cochrane review has found that the dose 
administered to MMT patients should ideally be in the order of 60–100 mg/day; when the agonist 
dose is too low, the risk of concurrent use of other drugs, such as cocaine, increases (Faggiano et al., 
2003). A second step would be to consider switching the agonist agent – several reviews have shown 
similar efficacy for methadone and buprenorphine (van den Brink and van Ree, 2003), whereas the 
efficacy of other agonists, such as codeine and slow-release oral morphine (SROM), remains to be 
proved in the future. However, a recent study has shown that methadone may be superior to 
buprenorphine for maintenance treatment patients with co-occurring cocaine and opioid dependence, 
being associated with longer periods of sustained abstinence and a greater proportion of drug-free 
tests (Schottenfeld et al., 2005). 
One important line of treatment of opioid dependence that is of particular interest in the case of those 
opioid-dependent subjects who are also using cocaine is the medical prescription of heroin to chronic, 
treatment-refractory heroin-dependent patients, an intervention that has been and will be tested in a 
variety of countries in Europe and North America (Fischer et al., 2002). Opioid-dependent patients 
who also use cocaine suffer from a more severe substance use disorder than non-cocaine-using 
opioid-dependent patients (Disney et al., 2005). Two reports about the Swiss experience concluded 
that supervised medical prescription of heroin is associated with good retention (70 % over 12 
months) and results in reduced opiates and cocaine  use in heroin-assisted clients (Rehm et al., 
2001; Güttinger and Rehm, 2005). However, as first reported in Farrell and Hall (1998), limitations in 
the original methodological design of the Swiss study raises questions on causality and thereby on 
interpretation of any consequently observed positive results as observed in the two mentioned studies 
above.     
In a recent report on two randomised controlled trials that were conducted in the Netherlands, 
combined treatment with methadone plus injectable or inhalable heroin was compared with treatment 
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with methadone alone while keeping the psychosocial treatment offer constant. The results of these 
trials were similar to those of the Swiss trials, but for the first time the observed improvements could 
be attributed to the medical prescription of heroin (van den Brink et al., 2003). Moreover, from a 
societal perspective, the co-prescription of heroin in this specific population was found to be cost-
effective compared with treatment with methadone alone (Dijkgraaf et al., 2005). Recently, similar 
results were reported from a small controlled trial from Spain and from a large RCT from Germany 
(manuscripts under review). In a recent Cochrane review, the authors stated that, based on the 
currently available results (not including the Spanish and the German data), no definitive conclusions 
about the overall effectiveness of heroin prescription was possible because of the non-comparability 
of the experimental studies (Ferri et al., 2005). However, reports of the German and Spanish data 
confirm the initial Swiss and Dutch results, showing a significant advantage of heroin/diamorphine 
over methadone treatment. Therefore, cocaine-using chronic opioid-dependent patients may be one 
of the target groups for heroin-assisted treatment.  
A number of studies have found that a longer period in treatment also resulted in reduced cocaine 
use among patients in MMT (Dobler-Mikola et al., 2005; Williamson et al., 2006b), although some did 
continue their cocaine use. In a Swiss study, 63 % of MMT patients used cocaine at treatment entry, 
and 37 % did so after 2 years (Dobler-Mikola et al., 2005). Magura et al. (2002) found no difference in 
reduction in cocaine use in MMT patients receiving either enhanced, intensive CBT or standard 
treatment. This lack of effect of treatment intensity has also been found in other clinical trials, but 
findings from the USA on this topic are inconsistent (Magura et al., 2002). Similar findings were 
obtained by Rawson et al. (2002), who compared two psychosocial approaches for the treatment of 
cocaine dependence: contingency management (CM) and CBT. Patients were randomly assigned to 
CM, to CBT, to combined CM and CBT or to treatment as usual (MMT only). The study findings 
provided solid evidence of the efficacy of CM and CBT, without evidence of an additive effect for the 
two treatments in the CM plus CBT group. Furthermore, a couple of studies have examined the 
combination of psychosocial interventions with other pharmacological agents in methadone-
maintained patients. Thus, one randomised double-blind study using desipramine with and without 
CM in cocaine-dependent methadone-maintained patients found that the combination of desipramine 
and CM had independent and additive effects in reducing cocaine use (Kosten et al., 2003). In 
another controlled study using bupropion with and without CM in cocaine-dependent methadone-
maintained patients, the combination of bupropion and CM significantly improved outcome (Poling et 
al., 2006). 
Other pharmacological agents have shown different results. In a trial comparing sustained-release d-
amphetamine with risperidone as an adjunct to MMT, risperidone showed no effect while sustained-
release d-amphetamine was found to be promising in the treatment of cocaine-dependent 
methadone-maintained patients (Grabowski et al., 2004b). In a trial studying methadone tapering plus 
amantadine to detoxify heroin-dependent cocaine users, amantadine did not show any efficacy with 
respect to retention in treatment or reduction in use or craving (Perez de los Cobos et al., 2001). A 
cost-effectiveness study on the adjunctive use of disulfiram in MMT found it to slightly increase the 
cost of MMT, but with an increase in effectiveness sufficient to warrant its use in cocaine-dependent 
methadone-maintained patients (Jofre-Bonet et al., 2004).  
In the United Kingdom, one-third of methadone patients are using crack at the time of entering 
treatment, a problem that may become worse even while treatment successfully reduces heroin use 
(NTA, 2002b). A United Kingdom study found a clear reduction in opiate use after motivational 
interviewing (MI) and pointed out the need to take into account additional non-prescribed drug use in 
general rather than specific crack use during MMT. It also demonstrated that it is feasible to integrate 
MI sessions into routine MMT practice (Mitcheson et al., 2007). 
3.5 Treatment of cocaine use in subjects with other psychiatric disorders 
The treatment of cocaine use in subjects with a comorbid psychiatric disorder has also been studied, 
particularly in four categories of patients: those with attention deficit hyperactivity disorder (ADHD); 
those with a depressive disorder; those with a bipolar disorder; and those with a schizophrenic or 
schizoaffective disorder. The main treatment strategy, similar to the treatment of cocaine-using 
opioid-dependent patients, is to optimise the treatment of the comorbid psychiatric disorder. 
Pharmacological strategies therefore involve those drugs generally used in the treatment of the 
psychiatric disorder, sometimes in combination with one of the drugs described in section 3.1. 
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The comorbidity of ADHD and cocaine dependence has not yet been sufficiently examined, but 
several studies point to the fact that the risk of developing cocaine dependence is higher in patients 
with a medical history of ADHD during childhood (Clure et al., 1999; Ros Soler et al., 2004; 
Rounsaville et al., 1991). Carroll et al. (1993) pointed out that a previous ADHD diagnosis is 
associated with earlier initiation of cocaine use and more frequent and severe cocaine use. The 
frequency of a previous ADHD diagnosis among cocaine-dependent subjects has been reported to be 
between 17 % and 40 % (Carroll et al., 1993; Castaneda et al., 1999). In the past ADHD was 
frequently not treated pharmacologically, with the result that many cocaine-dependent patients with a 
previous ADHD diagnosis profit from treatment with methylphenidate. Methylphenidate has been 
shown in several studies not only to lead to remission of ADHD symptoms, but also to attenuate 
cocaine use (Castaneda et al., 1999, 2000; Somoza et al., 2004), so that cocaine use has been 
understood to possibly be a self-medication of ADHD symptoms (Khantzian, 1985). However, there 
are also studies showing that methylphenidate is not effective in reducing ADHD symptoms or 
cocaine use (e.g. Levin et al., 2006) or reduces only ADHD symptoms but not cocaine use (Schubiner 
et al., 2002). Furthermore, there is concern about the abuse potential of methylphenidate, with some 
people expressing strong reservations about prescribing methylphenidate to ADHD patients who 
abuse psychoactive substances. Nonetheless, the evidence does not suggest that methylphenidate 
treatment in cocaine-abusing ADHD patients leads to increased abuse of either cocaine or 
methylphenidate (Collins et al., 2006). 
Recently, a new drug has been introduced for the treatment of ADHD – atomoxetine – which has 
similar efficacy to methylphenidate (Kratochvil et al., 2002). However, unlike methylphenidate, 
atomoxetine has been shown to have no craving-inducing properties in light drug users (Heil et al., 
2002), so that it could be considered the first-line treatment for ADHD in patients with additional 
substance use disorders (Wilens et al., 2003). Clinical experience has shown promising results in the 
treatment of ADHD and cocaine dependence (Haasen et al., 2005). However, there are as yet no 
controlled trials comparing the efficacy of atomoxetine and methylphenidate in cocaine-abusing 
ADHD patients. 
As is the case with all other classes of substance use disorders, cocaine dependence has been 
shown to be strongly associated with depression. However, there are great diagnostic difficulties in 
assessing a depressive disorder in cocaine-dependent subjects, as it is difficult to distinguish 
between the depressive symptoms caused in the initial phase of abstinence after cocaine use and an 
enduring depressive syndrome associated with an independent depressive disorder. Nonetheless, 
both depressive syndromes – that is, the ‘substance-induced’ and the independent syndrome – may 
require treatment with an antidepressant. A meta-analytical review of antidepressant efficacy for 
combined cocaine dependence and depression evaluated 11 RCTs: negative studies used SSRI 
treatment, while positive studies used agents such as desipramine or buproprion (Rounsaville, 2004). 
A more recent placebo-controlled study found desipramine to be effective in improving mood, which 
in turn was associated with reduced cocaine abuse without a clear direct effect of medication on 
cocaine outcome (McDowell et al., 2005). Another recent placebo-controlled study found that 
nefazodone treatment reduces cocaine craving, suggesting that this more modern antidepressant, 
which is also associated with fewer side-effects than desipramine, could be a promising drug for the 
treatment of cocaine-abusing depressive patients (Ciraulo et al., 2005b). 
Several studies have demonstrated an increased rate of comorbid substance use disorders in 
patients with bipolar disorder, with rates lying between 44 % and 61 % (Brown et al., 2001; Cassidy et 
al., 2001). Two substances have been explicitly tested for the treatment of cocaine-dependent 
subjects with a comorbid bipolar disorder – quetiapine and lamotrigine. The use of quetiapine was 
associated with substantial improvement in psychiatric symptoms and cocaine cravings, although 
cocaine use was not significantly decreased (Brown et al., 2002). Similarly, lamotrigine was 
associated with a statistically significant improvement in mood and drug cravings but not drug use 
(Brown et al., 2003a). Both substances warrant further research in larger samples. 
Treatment of cocaine dependence in patients with a comorbid schizophrenic or schizoaffective 
disorder has been examined in several studies. One of the main questions of interest was whether 
atypical antipsychotics have an advantage over typical antipsychotics in cocaine-abusing 
schizophrenic patients. An open-label pilot study compared risperidone with typical antipsychotics in a 
sample of cocaine-dependent schizophrenic patients, and found risperidone to be associated with 
lower cue-elicited craving and fewer substance abuse relapses (Smelson et al., 2002). A recent trial 
evaluating cocaine and amphetamine use in patients either continued or discontinued on a typical 
antipsychotic (and in part switched to an atypical antipsychotic) found a significant benefit in the 
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discontinuation group with respect to drug use (Brown et al., 2003b). The patients in the discontinued 
group who needed antipsychotic treatment were switched to quetiapine. Another case report, in which 
quetiapine was combined with gabapentin in the treatment of a cocaine-abusing patient with a 
schizoaffective disorder, showed a dramatic improvement with respect to psychiatric symptoms as 
well as reduction of cocaine cravings (Wayne and Madigan, 2004). A more recent trial comparing 
olanzapine with haloperidol found no significant difference in drug screens or psychiatric symptoms, 
while craving for cocaine was significantly lower in the haloperidol group than in the olanzapine group 
(Sayers et al., 2005). A third atypical antipsychotic, aripiprazole, was tested in a pilot study in 
cocaine-dependent schizophrenic patients, and showed possible effects in lowering both desire for 
and the use of cocaine (Beresford et al., 2005). In a review on the pharmacological treatment of 
patients with schizophrenia and substance use disorders, typical antipsychotics are described to be 
less effective than atypical antipsychotics (Tsuang et al., 2005), thereby contradicting the findings of 
Sayers et al. (2005). In summary, therefore, more rigorously controlled clinical trials are needed to 
determine the efficacy of atypical antipsychotics in the treatment of cocaine-dependent schizophrenic 
patients. 
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4 Psychosocial treatment  
Owing to the limited therapeutic benefits of pharmacological treatment for cocaine dependence, more 
emphasis has been put on psychosocial interventions to intervene in the addictive behaviour of 
cocaine-dependent persons. The roots of psychological treatments are embedded in behavioural and 
cognitive theories, including social learning theory (for an overview see Curran and Drummond, 
2005). On the one hand, behavioural theories define substance misuse as a set of learned or 
conditioned behaviours, which can be modified with specific therapies such as cue exposure 
treatment. On the other hand, cognitive theories are characterised by the existence of thoughts and 
beliefs (cognitions) that shape our behaviours and emotions, so that cognitive-related treatment 
consists in changing dysfunctional beliefs and maladaptive thoughts. Other models focus more on 
motivation and work with the client’s ambivalence about changing behaviour. Many treatments, 
however, combine elements of behavioural, cognitive and motivational approaches. 
The only RCT in the field of addiction in which the effects of psychosocial interventions have been 
systematically investigated can be found in relation to cocaine dependence. Thus, a multicentre 
investigation examined the efficacy of four different psychosocial interventions for cocaine-dependent 
patients (Crits-Christoph et al., 1999). The four types of interventions investigated in the study were 
cognitive psychotherapy, psychodynamic psychotherapy, individual counselling and group 
counselling, with the primary outcome being assessed on the basis of the Addiction Severity Index–
Drug Use Composite score and the number of days of cocaine use in the past month. The results 
showed that all psychosocial interventions had significantly reduced cocaine dependence, with both 
psychotherapies showing greater effectiveness for retention rates, while both counselling methods 
appeared to be more effective in terms of abstinence rates. 
Furthermore, evidence shows that even brief interventions have a positive influence on drug-using 
behaviour (Prinzleve et al., 2003; Mitcheson et al., 2007), although the best results are achieved by 
longer-term treatment (Thomasius et al., 2004). Unfortunately, as mentioned in Witton and Ashton 
(2002), comparative studies of psychotherapeutic approaches are lacking, while existing efficacy 
studies have mainly consisted in assessing the outcomes of single psychosocial approaches. Finally, 
an overview of the effectiveness of most psychosocial therapies in relation to specific substances has 
recently been published (Wanigaratne et al., 2005). The following sections in the present review 
describe various types of psychosocial treatments that are currently employed to treat substance 
dependence, including cocaine dependence.  
4.1 Cognitive–behavioural therapy (CBT) and other behavioural approaches 
CBT is based upon social learning principles. It focuses on the identification of cognitive and 
environmental factors controlling problem behaviour. The aim of this approach is that people learn 
alternative behaviours instead of behaviours related to cocaine use and learn to practise self-control 
strategies. CBT is a widely adopted approach to the treatment of cocaine dependence, particularly in 
the USA, and an extensive manual on CBT for cocaine treatment has been published, which offers 
guidelines for practitioners working with cocaine users (Carroll, 1998). Although CBT is usually 
associated with low retention rates, its main benefit appears to be moderation of consumption, and 
there are some suggestions that CBT works especially well with cocaine users presenting elevated 
intellectual capacity and users with comorbid depression or heavier addiction (Rigter et al., 2004). 
Furthermore, among the heaviest users, CBT seems to produce better results than psychotherapy 
and clinical care (NTA, 2002b). The extent to which participants complete homework assignments 
also appears to influence treatment outcome. Thus, during CBT and in the follow-up phase 1 year 
later, cocaine-dependent participants with a strong rate of completed homework showed significantly 
lower cocaine use (Carroll et al., 2005). 
These results suggest that willingness to complete extra session assignments is an important 
mediator of treatment response. However, cognitive-impaired users appear not to benefit fully from 
CBT as their dropout rate appears to be much higher than that of non-impaired users. Several studies 
have shown that retention and abstinence rates are much lower within the former group, with 
treatment ‘completers’ performing better on cognitive tests than dropouts (Aharonovich et al., 2003, 
2006). These results suggest that the cognitive abilities of the patient should be taken into 
consideration when choosing treatment settings, especially as empirical studies have shown that 
chronic cocaine use can have detrimental effects on cognitive functioning (e.g. Strickland et al., 
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1998). Finally, another study has shown that cocaine-dependent users presenting comorbid alcohol 
problems during behavioural treatment have lower cocaine abstinence rates than users who 
abstained from alcohol use at treatment entry (Mengis et al., 2002). 
In Europe, CBT or similar behavioural approaches are widely offered within general treatment 
facilities, but special units or facilities for cocaine users are limited. In Denmark, however, in an 
attempt to integrate and develop the experiences from other countries within a Danish treatment 
environment, the Copenhagen Municipality has allocated budget resources to a high-quality 
development programme, in which a relevant cocaine-related treatment concept will be tried out and 
which will include cognitive treatment with some degree of behavioural therapy elements (Danish 
national report, 2006). 
Furthermore, in November 2005 in Ireland, a number of pilot projects were conducted to examine 
methods of managing cocaine users. One of the goals of the projects was to train professional 
counsellors working with cocaine users to deliver more intensive, psychotherapeutic basis CBT-type 
interventions, with the aim of enabling practitioners to deliver appropriate interventions to 
cocaine/stimulant users. The syllabus provided at these training sessions introduced students to 
cognitive and behavioural learning theories of addiction and the research supporting this treatment 
approach. Specific skills were practised to enable practitioners to deliver competent, effective CBT 
interventions, brief interventions and motivational Interviewing. These included behavioural analysis 
of drug and alcohol use, coping skills, goal setting, planning and monitoring. This intensive training 
was completed over four intensive 2-day sessions. A total of 104 people, a mix of health service and 
community-based professionals and volunteers, participated and evaluated the training as highly 
helpful as it increased their skills and knowledge about working with cocaine users. The treatment 
intervention aspect of the project was piloted in four areas of Dublin. Each intervention focused on a 
different aspect of cocaine use (intravenous cocaine users, problematic intranasal cocaine users, 
female problematic cocaine users or polydrug cocaine users). The treatment intervention consisted of 
individual drug counselling, brief interventions, motivational interviewing and CBT. The evaluation of 
these interventions is currently being evaluated (NACD, 2007). 
In Portugal, pilot projects are under way to test two different treatment approaches to cocaine 
dependency, one strictly pharmacological and the other (mainly as a complement and frequently 
accompanied by the use of medication) through psychosociological support (Portuguese national 
report, 2006). Furthermore, in Germany, CBT or CBT-orientated treatment is offered for cocaine 
users in a small number of services, with specialised outpatient services being located in cities with a 
high prevalence of cocaine and crack abuse. Thus, Kokon (4), an independent drug service in Berlin, 
offers clients a first assessment phase of 4–6 months, and focuses on the clients’ preferred drug of 
consumption (cocaine or opiates). Thereafter, the treatment is continued as an integral programme 
for all kinds of drug users. Kokon is working with a cognitive–behavioural approach on the basis of an 
interactive personality model (Kokon, 1999; Tossmann et al., 2000; Stöver, 2001). The Seehaus-
Projekt, a special cocaine consulting and therapy service in Hamburg, follows a similar approach. The 
therapeutic programme, lasting up to 18 months, comprises an initial phase, during which the 
individual’s situation and treatment goals are clarified, followed by 8 months of CBT-type treatment. 
The remainder of the programme consists of a non-substance-specific phase of further consolidation 
(N. Essberger and A. Hansen, unpublished). 
A specialised outpatient service at the Hamburg University Department of Psychiatry comprises two 
parts and also has a sequential structure: an initial so-called ‘cocaine counselling hour’ for diagnostic 
and treatment planning and, if indicated, brief cognitive–behavioural training in coping skills. This two-
step approach was chosen to evaluate and detect conditions that frequently lead to treatment 
cessation, in particular psychiatric comorbidity and abuse of multiple substances. If psychotherapy is 
indicated, a brief cognitive–behavioural intervention is offered. This approach seems to be most 
appropriate for the main target group of the service, which are users with average consumption and 
for whom reduced or more controlled use is an acceptable aim. The first results are promising, but 
based only on a very small sample size (Prinzleve et al., 2003). A similar approach is followed by a 
treatment agency in the Swiss city of Winterthur (Schuetz, 2006).  
                                                     
 
(4) www.kokon.de. 
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In recent years, some inpatient institutions, particularly those located near cities with a relatively high 
prevalence of cocaine use, have started to offer inpatient treatment for cocaine-related problems. 
Most of these treatments have adapted CBT approaches for the individual treatment of cocaine and 
crack users. However, inpatient units targeting exclusively users of cocaine as the primary drug seem 
to be scarce, and studies concerning the effects of cocaine-specific treatment in residential treatment 
settings are lacking. 
Another form of behavioural intervention is the community reinforcement approach (CRA), which is a 
multifaceted behavioural treatment incorporating a range of interventions, including family 
counselling, stress management, social skills training and job counselling (Peele and DeGrandpre, 
1998). Reinforcers are used to reduce cocaine use and should, theoretically, be available in the 
community and incompatible with cocaine use. CRA is often but not always combined with CM (e.g. 
Higgins et al., 2003). Relatively positive results for this kind of treatment have been reported from the 
USA, in terms of both retention and abstinence rates. Higgins et al. (2003) found an increased 
retention rate for the combined therapy compared with voucher-only therapy (5). Roozen et al. (2004) 
reviewed 11 studies on the effectiveness of CRA and found that the combination with CM was more 
effective than CRA alone. A comparison of CRA with and without incentives found strong evidence 
that treatment with incentives is more effective with regard to abstinence in cocaine users. In the 
Netherlands, an experiment with CRA for cocaine users (with or without heroin addiction and in or out 
of methadone maintenance treatment) is in its last phase. It tests the applicability and effectiveness of 
the CRA combined with voucher incentives in the Dutch situation (Dutch national report, 2006).  
4.2 Rewards/punishment-based therapies 
CM treatment – also known as voucher-based therapy – is also based on behavioural principles. It 
makes use of ‘reinforcers’, usually vouchers for goods or services. Typically the value of the 
reinforcers increased during treatment on the basis of negative urinalysis. Cocaine abstinence is 
usually tested via urine a few times a week and rewards are given for negative tests. A number of 
studies have reported good results for CM. For example, Petry et al. (2005) found that retention rate 
and abstinence duration were increased in patients treated with CM plus reinforcers compared with 
patients undergoing CM alone. However, it also has to be noted that the effects of CM tend to 
dissipate after its discontinuation (e.g. Rawson et al., 2002; Roozen et al., 2004). When compared 
with CBT, the results of CM tend to be better during the treatment period, whereas CBT shows better 
outcomes during follow-up (e.g. Rawson et al., 2006). Furthermore, some studies have found that 
voucher reinforcement provides no additional benefit in the outpatient treatment setting (Katz et al., 
2002). Some authors have suggested that reinforcers ought to be suitably aspirational to be attractive 
to the user and, predictably, settings offering vouchers of higher value have been found to result in 
greater levels of abstinence (Petry et al., 2004). Of course, this does, however, mean that the costs of 
this kind of treatment are relatively high. Finally, it has been found that treatment results are best 
when rewards (and, by association, punishment) are handed out immediately after urine test results 
(NTA, 2002b).  
Studies have also been conducted on the effectiveness of incentive-based brief interventions. In one 
study Katz et al. (2002) found that the majority of MMT patients refrained from cocaine use for 2 days 
when offered a voucher for abstinence. What might be more important for treatment strategies is that 
these patients subsequently exhibit higher rates of immediate cocaine abstinence. Although the study 
found relatively high rates of relapse despite the continued availability of substantial monetary 
reinforcers, the authors considered the initial abstinence to be a positive start. 
Furthermore, research on CM as short-term intervention for cocaine users in MMT found significant 
improvement among those receiving CM compared with a control group who received only verbal 
encouragement to abstain (Sigmon et al., 2004). It made no difference whether the reward was given 
for a negative urinalysis on a quantitative or qualitative basis, although the sample size in all three 
groups was too small to draw any conclusions. In the quantitative method, a negative urinalysis is 
defined as a 50 % or greater reduction in urine benzoylecgonine concentration over 2 days (Preston 
et al., 1997). In contrast, in the qualitative urinalysis testing approach, the urine benzoylecgonine 
                                                     
 
(5) Voucher programmes provide motivational points for patients whose urine specimens test negative for cocaine: high-scoring 
patients receive vouchers that can be redeemed for rewards (such as clothing, rent payments, YMCA passes). 
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concentration must be below 300 ng/ml for the sample to be considered negative, so that participants 
may need to abstain from cocaine use for 2–5 days to produce a negative urine specimen. Thus, 
quantitative testing is considered to be more sensitive and allows the differentiation between ‘new’ 
cocaine use and carry-over from previous uses. As a direct consequence, this increased sensitivity 
reduces the delay between initiation of cocaine abstinence and reinforcement provision, which results 
in a more accurate implementation of the reinforcement contingencies (i.e. fewer instances of non-
reinforced abstinence) and possibly in increased treatment efficacy (Preston et al., 2001). 
In line with Preston et al. (2001), Katz et al. (2002) found that quantitative procedures produced better 
outcomes, which confirms that these are more accurate and relevant to brief periods of abstinence. 
Another variation of CM has been reported in which gradual cocaine abstinence is rewarded by 
handing out vouchers for decreased cocaine use (as determined by urine analysis) during the first 
weeks of treatment, as opposed to demanding total abstinence. This stepwise approach to CM 
resulted in better outcomes than standard CM (Preston et al., 2001). Finally, one modified form of this 
approach consists in using prizes as reinforcers, with clients being rewarded with opportunities to 
enter a draw to win different prizes of varying financial value. This has also been tested, with similar 
results to standard CM (Petry et al. 2005). As the prize system is more cost-effective, it is considered 
likely to become the method of choice (Petry and Martin 2002). Looking at the comparison between 
non-contingent and contingent vouchers, no causal relationship was found between non-contingent 
voucher receipt and increased drug use (Schroeder et al., 2003).  
Furthermore, CM programmes have shown specific value in the treatment of cocaine users with 
antisocial personality disorder (Messina et al. 2003). However, because of the short-lived effects of 
CM, combinations with other forms of treatment are often applied. The combination of CM with CRA 
is quite common, and an increased retention rate is one of the most reliable effects of combined CRA 
and voucher intervention (Higgins et al., 2003). When combined with behavioural day treatment, 
positive treatment outcome is twice as likely as with day treatment alone (Schumacher et al., 2003).  
Comparisons of CM and CBT have found solid evidence of efficacy for both types of treatment. 
Although CM appears to result in significantly better outcome during treatment, CBT shows better 
outcome in the long term, although both approaches combined showed no additive effect (Rawson et 
al., 2002, 2006). Another study even found that CBT had brief detrimental effects on the outcome of 
CM when both were combined (Epstein et al., 2003). A further treatment combination was 
investigated in homeless cocaine users (Milby et al., 2003, 2004, 2005). Thus, during behavioural day 
treatment, housing could be offered as a reward for abstinence. The group that was offered housing 
exhibited a better outcome, with more abstinent users, increased duration of abstinence and fewer 
patients relapsing compared with the group that received day treatment only (Milby et al., 2004). 
Another approach was used by a study that provided access to a ‘therapeutic workplace’ when 
urinalysis was found to be negative (Silverman et al. 2002). This approach was found to be 
particularly appealing to poor and long-term unemployed patients. 
Reinforcers are used to reward not only  negative urinalyses but can also the performance of tasks 
related to individual treatment, e.g. attending medical appointments or treatment sessions or 
achieving legal and money management tasks. This approach has been shown to result in better 
retention in MMT and a higher abstinence rate (Villano et al., 2002). 
In summary, the CM method has shown substantial efficacy in the treatment of cocaine dependence, 
but it remains to be seen whether CM can be adapted and implemented in a community-based 
setting (Petry and Simcic, 2002). Furthermore, this largely US approach has been very little 
implemented in Europe, and no data on voucher reinforcement from European countries are yet 
available. 
4.3 Motivational interviewing 
Motivational interviewing (MI) is an interventional approach with cognitive–behavioural basis used as 
a short-term intervention. It aims to support clients during the change process. It is a client-centred 
directive method for enhancing motivation to change problem behaviour, in this case problematic 
cocaine use, by exploring and resolving ambivalence. The concept of MI, established by Miller and 
Rollnick (1991), centres on the intrinsic ambivalence of the problematic user. The main purpose of MI 
is the examination and resolution of ambivalence, and the counsellor is intentionally directive in 
pursuing this goal. The guiding principle is to actively support the client’s decision to bring about the 
change. The four main principles of MI are: 
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• express empathy; 
• develop discrepancy; 
• roll with resistance; 
• support self-efficacy.  
Furthermore, MI is characterised by a number of distinct working methods such as asking questions, 
summing up the important arguments of the client and reflective listening (Körkel and Veltrup, 2003). 
Research has shown that motivational enhancement is more beneficial for clients with lower initial 
motivation to change than for those with higher motivation (Rohsenow et al., 2004). MI in the form of 
brief intervention (one session of MI) has also been shown to have positive outcomes with regard to 
abstinence (Bernstein et al., 2005). 
MI appears to be used in a number of European countries and in different treatment settings. In 
Germany, MI as part of an individual case management approach (Schmid and Vogt 2001), as well 
as integrated in other types of individual intensive treatment, is found to be effective for different types 
of cocaine users (Stöver, 2001). In the United Kingdom, Thom (2001) highlighted the common pairing 
of alcohol and cocaine and the potential of MI to indirectly address cocaine use through alcohol 
problems. Several Spanish literature reviews have found that optimal treatment involves a 
combination of psychotherapy – using relapse prevention techniques and MI – and pharmacological 
treatment with anxiolytics (Garcia et al. 2001; San Molina and Arranz Diez, 2001; Sole Puig, 2001).  
4.4 Relapse prevention 
As mentioned earlier, psychosocial interventions, which are based on social learning theories, are 
used to provide users with the coping skills and protective techniques they need to cope with relapse 
triggers. These can include lifestyle and cognitive strategies. Among cognitive–behavioural strategies, 
a United Kingdom review identified the following as vital for a minimum satisfactory result 
(Wanigaratne et al., 2005): 
• identifying high-risk situations and triggers for craving; 
• developing strategies to limit exposure to high-risk situations; 
• developing skills to manage cravings and other painful emotions without using substances; 
• learning to cope with lapses; 
• learning how to recognise, challenge and manage unhelpful or dysfunctional thoughts about 
substance use; 
• developing an emergency plan for coping with high-risk situations when other skills are not 
working; 
• generating pleasurable sober activities and relationships, building a life worth living and attaining 
a lifestyle balance. 
In addition, the following approaches have been found to increase success rates of abstinence: 
thinking about positive and negative consequences; alternative behaviours; relaxation; meditation; 
seeking social support; offer refusal; spiritual methods; problem-solving; working towards goals, clean 
recreation; not carrying much money; keeping busy; thinking about consequences (Rohsenow et al., 
2005). The same authors also suggested concentrating on enhancing the cognitive and lifestyle skills 
that have proven efficient for the user. Interestingly, another study by the same authors found that the 
use of coping skill training in group therapy was more beneficial to women than to men in terms of 
reducing cocaine and alcohol use (Rohsenow et al., 2004). The authors suggested that group 
settings allow less attention on individual specific issues, which appear to be crucial for developing 
cognitive coping skills, and that women may be more likely to open up in a group setting than men, 
who often reported fearing to disclose illegal activities in a group. 
In Spain the most frequently used psychotherapeutic treatment approach is the relapse prevention 
model proposed by Marlatt and Gordon, which consists in cognitive restructuring, and the learning of 
confrontation and problem resolution skills (Marlatt and Gordon, 1985). Prochaska y Di Clemente’s 
change process model is also frequently used, which involves matching treatment strategies with the 
patient’s stage of readiness for change (Pedrero Pérez and Puerta Garcia, 2001). Finally, according 
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to Wanigaratne and colleagues, relapse prevention is among the most common approaches used in 
the treatment of cocaine users in the United Kingdom (Wanigaratne et al. 2005). 
4.5 Family therapy 
The term family therapy is used to describe a variety of family interventions, all sharing the common 
characteristic of involving the user’s family or closer social network in treatment. Family therapy works 
towards altering family structures using a non-blaming, non-judgemental approach with a strong 
emphasis on behaviourism (Wanigaratne et al., 2005). The integration of the family into the treatment 
process can be of considerable importance, particularly in the case of adolescent cocaine users 
(Thomasius et al., 2004). No recent research on family therapy has been conducted, but two earlier 
randomised clinical trials found that treatment involving family therapy was associated with a better 
outcome than standard treatment (McLellan et al., 1993; Fals-Stewart et al., 1996). 
4.6 Counselling 
Wanigaratne et al. (2005) defined counselling as a humanistic, client-centred, non-directive approach 
to the problems presented by the individual. Structured drug counselling can have positive results for 
most cocaine users and can be offered as individual or group counselling, each with different base 
guidelines. Counselling typically comprises a well-structured psychosocial procedure, and is usually 
based on a procedural manual that includes, for example, an individual care plan. Weiss et al. (2003) 
used a ‘cocaine craving questionnaire’ to predict cocaine use in the week following psychosocial 
treatment. They reported that the relationship between craving and subsequent cocaine use varied by 
treatment condition. Thus, the authors compared CBT plus group counselling, psychodynamic 
therapy plus group counselling and group counselling alone, and found a combination of individual 
and group drug counselling to be the most successful treatment method. However, although such 
combination treatments seemed to be the most successful in reducing cocaine craving, it remained 
unclear exactly which aspects of individual and group counselling were the most beneficial. Finally, 
Kletter (2003) also found that cocaine use in users was reduced during court-enforced counselling.  
4.7 Other approaches  
The Minnesota method (12-step), which originated in the USA, is an approach based on the self-help 
philosophy of Narcotics Anonymous and Alcoholics Anonymous. According to Wanigaratne et al. 
(2005), the 12-step approach regards ‘addiction as a relapsing illness with complete abstinence as 
the only treatment goal. As part of the process towards recovery, individuals must acknowledge to 
themselves (and other people) the harm that substance use has caused to themselves and others 
and where possible make amends’. There is, however, hardly any evidence-based research on the 
effectiveness of this approach. However, Weiss et al. (2005) found active 12-step group participation 
by cocaine-dependent patients to be more efficient than meeting attendance alone, which was 
reflected by a decrease in cocaine use among the active participants. The authors also found an 
increase in effectiveness for treatments that combine individual drug counselling and active 12-step 
participation. Furthermore, Crits-Christoph et al. (1999) found that clients receiving 12-step individual 
counselling in addition to group drug counselling were more likely to achieve and maintain abstinence 
than those receiving other studied interventions (cognitive therapy plus group drug counselling or 
group drug counselling alone). The same authors also found engagement in the 12-step activities to 
be a partial statistical mediator of drug use outcomes (Crits-Christoph et al., 2003). The Minnesota 
method has also achieved a long tradition in European countries, and research carried out in Italy 
found good results of this method when combined with a psychodynamic intervention (Conte et al., 
2006). McKay et al. (2004) examined a telephone-based continuing care programme for cocaine and 
alcohol dependence. With respect to abstinence-related outcomes, the study found no differences 
between those groups that received either relapse prevention or 12-step group counselling and the 
control groups.  
A recent innovative strategy examined the effect of providing mobile phones to homeless crack 
cocaine-addicted users (Freedman et al., 2006). Users were asked to record current states of cocaine 
craving and use episodes, and also received computer-automated telephone interviews. Participants 
indicated that the survey made them more aware of phenomena leading to cravings and use, and it 
was suggested that such mobile phone reporting approaches could be considered a potentially useful 
intervention. 
EMCDDA literature reviews — Treatment of problem cocaine use 
 
 
 
30
Other types of interventions that have been tested with cocaine users include special group 
interventions, such as ‘anger management’ groups (Reilly and Shopshire, 2000), and, according to 
several German studies, an extended version of the individual case management approach has 
shown promising effects (Schmid and Vogt, 2001; Wendt, 2001). ‘Cue exposure’ therapy, based on 
learning theory principles, has also been proposed for the treatment of cocaine dependence. This 
particular approach typically involves repeated exposure to stimuli previously associated with drug 
use and aims at ‘deconditioning’ the user’s responses (Hamilton et al., 1998; Modesto-Lowe and 
Kranzler, 1999). Nonetheless, the cue exposure approach has, to date, shown little efficacy, and 
some authors have even suggested abandoning this approach or combining it with some other 
intervention such as coping response training (Conklin and Tiffany, 2002).  
Acupuncture therapy is also believed to decrease craving for cocaine and is gaining in popularity 
across Europe (Haasen et al., 2003b). Studies evaluating the efficacy of acupuncture have, however, 
shown conflicting results. One study found that cocaine-dependent, methadone-maintained patients 
were significantly more likely to provide cocaine-negative urine samples than were control groups 
(e.g. those receiving random needle insertion or only relaxation therapy) (Avants et al., 2000), 
whereas others did not find any effectiveness. Recent reviews have confirmed that the existing 
evidence fails to document the benefit of acupuncture in treating cocaine addiction as the sole 
treatment (Kim et al., 2005; Gates et al., 2006). However, one study showed possible benefits of 
acupuncture when used as an adjunctive treatment (Kim et al., 2005) . A recent Cochrane review 
came to the conclusion that the evidence of a benefit of acupuncture is inconclusive and lacks quality 
but nonetheless warrants further randomised trials (Gates et al., 2006). Finally, even if results are not 
conclusive, it has been suggested that acupuncture may still be a useful tool to retain users in 
treatment (NTA, 2002b). 
Finally, a total of 123 experts, including members of the CocinEU team (6) as well as well-known 
clinicians in Europe, were surveyed to report activities that could be relevant for this review. The 
results of the survey showed that the majority of European clinicians is currently treating cocaine-
dependent patients with pharmacological or established psychosocial treatment options. Only two 
innovative treatment strategies were identified that were not based on published research on the 
treatment of cocaine dependence. One is a psychosocial intervention, the other a pharmacological 
option, both originating from the psychiatric hospital Vall d’Hebron in Barcelona, Spain (director: 
Professor Miguel Casas). The psychosocial intervention consisted in the addition of psychoeducation 
to standard pharmacological treatment. The pharmacological option involved an RCT of the use of a 
methylxanthine (caffeine) in the treatment of cocaine dependence. 
Psychoeducation as a tool in the treatment of mental health disorders has been more widely used in 
the last 10 years, particularly for the treatment of schizophrenia. The positive outcome in the 
treatment of schizophrenia has led to a spread to treatment of other mental health disorders, 
including substance use disorders. However, little research has been published in this area. The use 
of psychoeducation in the treatment of cocaine dependence is in some ways similar to the use of 
other interventions offering advice and information (see section 5). It differs, however, in having a 
more structured approach in the group setting and in its aim of empowering individuals to cope with 
their cocaine problem.  
The use of caffeine for cocaine dependence can be considered as a treatment option similar to other 
options using stimulants as substitution agents (see section 3.1). The effect of caffeine to some 
extent imitates the effect of cocaine, so that the desire to use cocaine is diminished. To avoid the 
usual rapid development of tolerance, the anticholinergic agent biperidene is added. A randomised 
double-blind trial is under way (M. Casas, personal communication), comparing placebo with caffeine 
only and with a combination of caffeine and biperidene. The RCT has been accepted by the 
responsible ethics committee on the basis of findings in animal studies and considering the relatively 
low efficacy of pharmacological treatment of cocaine dependence so far. The results are expected 
during 2007. 
 
                                                     
 
(6) http://www.zis-hamburg.de/forschung_kokain_eu.de.html#centers. 
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5 Harm reduction 
It is recommended that general advice and information for drug users should be made available to 
anyone who seeks it on an ‘open access’ basis, i.e. in places such as public libraries, hospitals, 
government information offices, via telephone helplines and/or on the Internet. Information should 
include advice on the drug and its potential effects, and on harm reduction and treatment possibilities, 
and should also discuss the drug in terms of its potential consequences on other aspects of the user’s 
life such as housing, health, education and employment. With regard to assessment upon treatment 
entry, it is important for cocaine users that the first contact is made without delay and the client is 
helped to maintain further treatment sessions (NTA, 2002b). This kind of help is often part of general 
treatment or intervention practice, and is usually not focused purely on cocaine users, often forming 
part of a general harm reduction programme. For example, in Spain the general programme of 
intervention includes advice for medical professionals on how to treat cocaine users (Ramon and 
Torrecilla, 1999). Telephone helplines, as well as helplines on the internet, are other possible 
methods of providing information. They are provided in most countries, and offer the benefit of being 
confidential and accessible at any time.  
There are different harm reduction measures aimed at reducing the relative risks associated with drug 
misuse and in turn promoting better health and social life conditions for cocaine users. Cocaine use 
has been associated with high levels of injecting and sexual risk behaviour (Weiss, 1989). Low-
threshold (low barrier-to-entry) measures such as quiet rooms, measures to control use (Prinzleve et 
al., 2002) and measures to ensure quality of the substance (Decorte, 2001) may be implemented, as 
well as syringe exchanges for injecting users and counselling on health problems of any kind but in 
particular blood-borne diseases (BBDs). It has been suggested that harm reduction strategies be 
tailored to the needs of cocaine users, which may differ from other drug users’ experiences. It has 
been suggested that harm reduction should be available before, during and after structured treatment 
(NHS, 2005). 
Research has highlighted the difficulties that mainstream services experience in engaging with 
chaotic and erratic users, characteristics associated with sporadic binge patterns of cocaine use, and 
the need to offer flexible and immediate walk-in services rather than scheduled appointments, which 
clients fail to make use of (Haasen et al., 2003b). To counteract the stimulant qualities of cocaine, 
drug services have been advised to offer a calming, tranquil environment, with rooms in which to 
relax, and which serve as a forum for making contact (Stöver, 2002). In order to build overlap with the 
hours during which use typically takes place, opening hours might need to be more flexible (evenings 
and weekends) than has traditionally been the case. 
One of the most in-depth sources of evidence comes from Seivewright et al. (2000), who conducted a 
postal survey of all known drug misuse treatment services in the UK. Fifty per cent of services 
responded (n = 318), 53 % of which reported cocaine users presenting for treatment in the previous 6 
months. In general, the survey revealed that the services adopted a broad-based approach, not 
specific to cocaine problems, with a very practical approach to addressing general living problems 
and harm reduction techniques, which staff rated as more effective than short-term measures.  
Most harm reduction measures do not focus specifically on cocaine users but instead target all users 
of illicit drugs, based on an understanding that many drug-related problems – criminal contacts, 
imprisonment and criminal records, marginalisation, financial and housing problems, stigmatisation, 
etc. – are linked to the illegal status of substances and only to a lesser degree to the properties of the 
substances themselves.  
There is some evidence that harm reduction measures may decrease mental health problems as 
these are connected with the intensity of use (Haasen et al., 2005). Special treatment for crack 
cocaine users is offered in some of the cities where crack cocaine prevalence is highest, such as 
London, Frankfurt, Vienna and Barcelona (EMCDDA, 2005). 
In the German addiction services system, particularly in Frankfurt and Hamburg, the effectiveness of 
programmes for the emerging group of crack users has been intensively discussed. The city of 
Frankfurt, in particular, has responded to increased prevalence by intensifying its efforts to access 
this target group. In 1995, the Crack-Street-Projekt was initiated, an inter-institutional project involving 
different drug help services located in the city centre. The main institutions working together in this 
project are the local ‘AIDS-Hilfe’, running a consulting and care centre with an integrated consumption 
room, a local healthcare institution and a street work project, Walkman, which focuses on homeless 
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crack users in the main station area (Crack-Street-Projekt, 1998; Roth, 1999). In Hamburg the 
streetwork project Laufwerk already existed before the increase in problems with crack users in the 
area around Hamburg’s main station (Grosche and Voges, 2000). While this project officially focuses 
mainly on transient and homeless drug users, it also reaches crack cocaine users..  
Other harm reduction projects have also had to modify their work as a result of the increasing number 
of cocaine and crack users. Discussion has centred on the problems of low-threshold and walk-in 
services when confronted with large numbers of (sometimes aggressive) crack users. Accordingly, 
some experts have demanded more specific harm reduction offers for cocaine and crack users and 
more intensive networking among existing facilities. Because of the stimulant qualities of crack, it has 
been proposed that services should offer a calming, stress-free environment (Stöver, 2002). Various 
other measures have been suggested, ranging from the development of more specific information 
and harm reduction materials to the extension of supervised consumption rooms (Stöver, 2001; 
Dworsky, 2002; Haasen et al., 2004, 2005). In addition to existing harm reduction leaflets targeted at 
crack users, suggestions have been made on peer involvement in practical work and prevention 
campaigns as well as on the development of self-control strategies for cocaine and crack users 
(Stöver, 2001). 
Another helpful measure seems to be the establishment of so-called chill-out rooms or daytime rest 
rooms (Tagesruheräume) for cocaine and crack users. In Frankfurt, there are special rest rooms with 
10 day-sleeping beds and 23 emergency beds for people primarily using crack (Vogt et al., 2000; 
Stöver, 2001). Recently, rest rooms for crack users were introduced in Hamburg as well, which are 
integrated within a low-threshold drug help centre. This centre includes counselling, medical and 
psychiatric help, a consumption room and a shelter. 
Finally, experts offer little consensus on the usefulness of consumption rooms for crack and/or 
freebase users, or of ‘smoke sites’ (Rauchplätze) within existing consumption rooms for opiate users. 
Some believe that special consumption rooms for crack and/or freebase users are not useful or 
practical because of the often highly kinetic or agitated state of crack users (Stöver, 2001). On the 
other hand, there are consumption rooms with special sites for cocaine and crack users, thus 
succeeding in gaining access to this poorly reached group without major problems being reported 
(Poschadel et al., 2002;,Verthein et al., 2001; Zurhold et al., 2001; Vogt and Zeissler, 2005). 
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6 Inpatient treatment  
Inpatient treatment is characterised by staying overnight in a treatment facility, and can roughly be 
divided into emergency and short-term interventions, for example in general hospital psychiatric units 
or in drug detoxification units that are not specifically designed for cocaine users but offer general 
emergency healthcare assistance, and into longer-term treatment such as residential rehabilitation. 
However, short-term interventions and detoxification treatments do not necessarily lead to longer-
term treatment and are generally not suited to cocaine users, as indicated by the following study. Day 
et al. (2005) surveyed 91 British inpatient detoxification units and found that, during 2003/2004, 
approximately 6 829 admissions were to specialised units (services treating solely with substance 
misuse in either stand-alone facilities or wards within psychiatric or general medical facilities) and 
about 2 077 admissions were to non-specialised units (psychiatric or acute medical wards that are 
theoretically available for drug users, but in practice are occupied by general or medical psychiatric 
patients), while only one-fifth of admissions (1 805) were to residential rehabilitation settings. The last 
facilities are usually characterised by the provision of medically assisted detoxification as a prelude to 
longer residential treatment. Furthermore, the study showed that the average length of stay ranged 
from 4 to 77 days, with specialised units reporting longer durations of treatment. However, the same 
survey found that only 17 of the specialised units and 16 of the non-specialised services required 
patients to have an aftercare plan in place prior to admission, while only one-third of the admissions 
were discharged to residential or day care rehabilitation services. Finally, the study showed that 
services tended to be mainly dedicated to the treatment of opioid misuse and presented a clear lack 
of provision for poly-substance and stimulant (cocaine/crack and amphetamine) misusers.  
In Germany, immediate access to detoxification and treatment without a waiting period also targets 
crack users. The roots of this initiative, Therapie sofort (Therapy now), can be traced back to a 
national model project from the early 1990s, set up in response to an increasing number of drug-
related deaths. 
Generally, during inpatient treatment, a range of diverse measures aimed at improving aspects of the 
user’s life other than substance use-specific problems are offered. Treatment approaches in 
residential settings are not uniform and can include coping skills training as well as behavioural 
interventions, while some programmes have a religious or other ideological foundation. As there is a 
clear relationship between time spent on a programme and the probability of relapse for a number of 
(inpatient) treatments (Fernandez-Hermida et al., 2002), focus on how to keep people motivated for 
treatment has been prioritised. Residential rehabilitation seems to be especially successful for users 
with considerable problems in the emotional or psychiatric area and those with low levels of social 
support (e.g. homeless or long-term unemployed users) (NTA, 2002b). However, a recent study 
found that some groups of cocaine users, for example with a stable social background, do better in 
outpatient than in inpatient treatment (Ford, 2004). 
Cost-effectiveness must also be considered when setting up treatment programmes. Group 
counselling has been shown to be as effective as individual counselling except for the treatment of 
problematic users and has the benefit of being much cheaper for the community. Furthermore, a 
study by Simpson et al. (1999) examined the relationship between the length of stay and the severity 
of psychosocial problems in cocaine-dependent users, and their results confirmed that the patients 
with the most severe problems were more likely to be found in long-term residential programmes. In 
addition, they analysed the outcomes reported by those treated for 90 days or longer and found that 
better outcomes for patients with medium- to high-level problems are associated with longer 
treatment stays. However, duration of treatment alone has been found not to be an indicator of better 
outcome of a study on different treatment approaches; however, this research did not specifically 
focus on cocaine but included other drug use treatment as well (Zhang et al., 2003). 
One form of residential rehabilitation is the ‘therapeutic community’ (TC), which is usually a relatively 
long-term intervention. Originally orientated towards opiate users, interventions also exist for multiple 
substance users. Key elements of the TC approach are the orientation towards building long-term 
relationships between the agency and patients and the employment of former users as therapeutic 
agents (Thomasius et al., 2004). The concept of TCs originated in the USA and spread to European 
countries. A study by Fernandez-Hermida et al. (2002) measured outcomes of a TC for drug users 
(not cocaine specific) in Spain and found low retention rates (less than 50 %), which can be 
considered as typical for drug-free programmes. However, outcomes among treatment completers – 
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a self-selected group – were found to be very positive, as dropouts showed significantly higher rates 
of relapse and, moreover, relapses were more severe and lasted longer.  
 
7 Aftercare 
Aftercare consists in supporting clients after they leave structured treatment. It can include drug-
related interventions, such as MMT for stabilised opiate users (NHS, 2005), harm reduction and also 
non-drug-related help with, for example, housing or education. Aftercare programmes can include 
support groups, individual sessions or self-help groups. It has been suggested that support should be 
made available both immediately after structured treatment as well as later, depending on the needs 
of the client.  
In the USA, self-help groups are often based on Cocaine Anonymous, a variant of Alcoholics 
Anonymous. These groups mainly work with the 12-steps programme, based on more or less 
religious or spiritual ideas, and aim at mutual support. In Europe, Cocaine Anonymous groups exist in 
the United Kingdom (17 cities), the Netherlands (2), Spain (2), France, Sweden, Germany, Greece, 
and Belgium (Cocaine Anonymous, 2006). Other forms of self-help groups working with similar 
principles also exist in most countries. 
Some studies have found reduced drug use among those attending self-help groups, while others 
have not found any difference (Broome et al., 2002). An explanation for different study outcomes has 
been suggested to lie in the spiritual beliefs or ideology underpinning the setting. Hence, for some 
participants this aspect might engender stronger social support (Broome et al., 2002).  
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8 Conclusion  
In summary, the treatment of cocaine dependence frequently still includes the use of antidepressants, 
especially SSRIs, despite the low evidence level for their efficacy. More promising results are 
expected from topiramate and other antiepileptic drugs, and much hope is being placed in the 
development of the cocaine vaccine. Because of the lack of effective pharmacological treatment, 
European clinicians working with cocaine-dependent clients rely mostly on psychosocial interventions 
to reduce cocaine-related problems. These interventions involve mainly drug counselling such as 
Motivational Interviewing and case management, as well as CBT, but promising results have been 
reported from the USA using an incentive-based approach, namely Contigency Management. 
Furthermore, outpatient treatment, in contrast to residential rehabilitation, appears to be better suited 
to the treatment of most cases of cocaine dependence. Nonetheless, the efficacy of cocaine 
treatment is still considered to be much lower than the efficacy of treatment options for opioid 
dependence.  
Concerning the research situation in general, it has to be pointed out that a huge body of evidence 
comes from international studies, most of them originating in the USA. These international studies 
have uncovered many issues related to cocaine use, its consequences and the treatment of cocaine 
problems, and not all of these findings are limited to the USA. Nevertheless, there is an urgent need 
for research concerning problematic cocaine use in relation to the European treatment context.   
Furthermore, as clearly reflected by cocaine use patterns, polydrug use has become the rule with  
important gaps in our knowledge about treatment and harm reduction responses to multiple drug use 
being brought to light. Research dealing with this topic is therefore urgently required.  
There is also a need for studies investigating the reasons for the differences in the prevalence of 
crack cocaine use between European countries and within individual European countries. The 
evidence so far shows that the use of crack cocaine has to be considered on a local level, taking into 
account the social environment (e.g. poverty, marginalization) and cultural diversity as well as locally 
predominant consumption patterns.  
Both issues, multiple substance use and the differences in crack cocaine use, have an important 
influence on the choice of treatment, including harm reduction measures for problems in connection 
with cocaine use. There is evidence that multiple substance use in general has a negative impact on 
treatment outcomes, and often masks what might be an effective treatment for cocaine problems. 
Some evidence suggests that there are differences in the treatment outcome between crack cocaine 
users and cocaine powder users, which in turn might be related to different patterns of multiple 
substance use. Harm reduction measures developed for problems related to the use of opiates have 
to be further developed and matched to the specific harm problems of cocaine use. 
The social context plays an important role in psychosocial interventions, and approaches used in the 
USA have only limited transferability to the European context. However, in the case of 
pharmacological treatments, including the cocaine vaccine, results can be more easily transferred, as 
the neurobiological basis for these interventions is not as strongly affected by cultural differences. As 
highlighted by this review, there is an urgent need to carry out large trials on psychosocial 
interventions among cocaine-dependent populations treated in Europe.  
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